AVITA Medical (RCEL) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 02, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	AVITA MEDICAL, INC.
Entity Central Index Key	0001762303
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Security Exchange Name	NASDAQ
Trading Symbol	RCEL
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Interactive Data Current	Yes
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	DE
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		25,478,301
Entity File Number	001-39059
Entity Tax Identification Number	85-1021707
Entity Address, Address Line One	28159 Avenue Stanford
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Valencia
Entity Address, Postal Zip Code	91355
City Area Code	(661)
Local Phone Number	367-9170

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 37,485	$ 18,164
Marketable securities	28,562	61,178
Accounts receivable, net	5,754	3,515
BARDA receivables	442	898
Prepaids and other current assets	2,194	1,578
Inventory	3,058	2,125
Total current assets	77,495	87,458
Marketable securities, long-term	2,754	6,930
Plant and equipment, net	1,598	1,200
Operating lease right-of-use assets	1,651	851
Corporate-owned life insurance asset	2,091	1,238
Intangible assets, net	456	465
Other long-term assets	285	122
Total assets	86,330	98,264
LIABILITIES, NON-QUALIFIED DEFERRED COMPENSATION PLAN SHARE AWARDS AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	3,837	3,002
Accrued wages and fringe benefits	6,200	6,623
Current non-qualified deferred compensation liability	2,572	78
Other current liabilities	1,201	990
Total current liabilities	13,810	10,693
Non-qualified deferred compensation liability	1,224	1,270
Contract liabilities	374	698
Operating lease liabilities, long-term	1,047	306
Total liabilities	16,455	12,967
Non-qualified deferred compensation plan share awards	1,228	557
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 25,447,615 and 25,208,436 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	3	3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at June 30, 2023 and December 31, 2022.	0	0
Company common stock held by the non-qualified deferred compensation plan ("NQDC Plan")	(892)	(127)
Additional paid-in capital	343,769	339,825
Accumulated other comprehensive income	7,959	7,627
Accumulated deficit	(282,192)	(262,588)
Total stockholders' equity	68,647	84,740
Total liabilities, non-qualified deferred compensation plan share awards and stockholders' equity	$ 86,330	$ 98,264

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement Of Financial Position [Abstract]
Common stock par value	$ 0.0001	$ 0.0001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	25,447,615	25,208,436
Common stock shares outstanding	25,447,615	25,208,436
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues	$ 11,753,000	$ 8,335,000	$ 22,303,000	$ 15,874,000
Cost of sales	(2,204,000)	(1,386,000)	(3,871,000)	(3,164,000)
Gross profit	9,549,000	6,949,000	18,432,000	12,710,000
BARDA income	530,000	551,000	1,157,000	1,285,000
Operating expenses:
Sales and marketing expenses	(10,003,000)	(5,332,000)	(16,543,000)	(10,160,000)
General and administrative expenses	(6,165,000)	(5,471,000)	(14,460,000)	(13,005,000)
Research and development expenses	(5,076,000)	(3,059,000)	(9,662,000)	(6,679,000)
Total operating expenses	(21,244,000)	(13,862,000)	(40,665,000)	(29,844,000)
Operating loss	(11,165,000)	(6,362,000)	(21,076,000)	(15,849,000)
Interest expense	(7,000)	(4,000)	(11,000)	(4,000)
Other income	801,000	109,000	1,526,000	137,000
Loss before income taxes	(10,371,000)	(6,257,000)	(19,561,000)	(15,716,000)
Income tax expense	(13,000)	(4,000)	(43,000)	(8,000)
Net loss	$ (10,384,000)	$ (6,261,000)	$ (19,604,000)	$ (15,724,000)
Net loss per common share:
Basic	$ (0.41)	$ (0.25)	$ (0.78)	$ (0.63)
Diluted	$ (0.41)	$ (0.25)	$ (0.78)	$ (0.63)
Weighted-average common shares:
Basic	25,239,723	24,971,243	25,221,009	24,954,712
Diluted	25,239,723	24,971,243	25,221,009	24,954,712

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (10,384)	$ (6,261)	$ (19,604)	$ (15,724)
Other comprehensive income gain/(loss):
Foreign currency translation gain/(loss)	1	(110)	(10)	(92)
Net unrealized gain/(loss) on marketable securities, net of tax	100	(135)	342	(432)
Comprehensive loss	$ (10,283)	$ (6,506)	$ (19,272)	$ (16,248)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Company Common Stock Held by the NQDC Plan	Additional Paid-in Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2021	$ 104,624	$ 3		$ 332,484	$ 8,060	$ (235,923)
Beginning balance, shares at Dec. 31, 2021		24,925,743
Net loss	(15,724)					(15,724)
Stock-based compensation	4,346			4,346
Exercise of stock options	1			1
Exercise of stock options, shares		125
Vesting of restricted stock units, shares		77,220
Change in classification of deferred compensation share awards	(192)			(192)
Change in redemption value of share awards in NQDC plan	29			29
Other comprehensive gain (loss)	(524)				(524)
Ending Balance at Jun. 30, 2022	92,560	$ 3		336,668	7,536	(251,647)
Ending Balance, shares at Jun. 30, 2022		25,003,088
Beginning Balance at Dec. 31, 2021	104,624	$ 3		332,484	8,060	(235,923)
Beginning balance, shares at Dec. 31, 2021		24,925,743
Ending Balance at Dec. 31, 2022	84,740	$ 3	$ (127)	339,825	7,627	(262,588)
Ending Balance, shares at Dec. 31, 2022		25,208,436
Beginning Balance at Mar. 31, 2022	97,815	$ 3		335,417	7,781	(245,386)
Beginning balance, shares at Mar. 31, 2022		24,955,581
Net loss	(6,261)					(6,261)
Stock-based compensation	1,414			1,414
Vesting of restricted stock units, shares		47,507
Change in classification of deferred compensation share awards	(192)			(192)
Change in redemption value of share awards in NQDC plan	29			29
Other comprehensive gain (loss)	(245)				(245)
Ending Balance at Jun. 30, 2022	92,560	$ 3		336,668	7,536	(251,647)
Ending Balance, shares at Jun. 30, 2022		25,003,088
Beginning Balance at Dec. 31, 2022	84,740	$ 3	(127)	339,825	7,627	(262,588)
Beginning balance, shares at Dec. 31, 2022		25,208,436
Net loss	(19,604)					(19,604)
Stock-based compensation	3,372			3,372
Exercise of stock options	$ 832			832
Exercise of stock options, shares	146,529	146,529
Company common stock held by the NQDC plan			(765)	765
Company common stock held by the NQDC plan, Shares		87,650
Vesting of restricted stock units, shares		5,000
Change in redemption value of share awards in NQDC plan	$ (1,025)			(1,025)
Other comprehensive gain (loss)	332				332
Ending Balance at Jun. 30, 2023	68,647	$ 3	(892)	343,769	7,959	(282,192)
Ending Balance, shares at Jun. 30, 2023		25,447,615
Beginning Balance at Mar. 31, 2023	77,561	$ 3	(892)	342,400	7,858	(271,808)
Beginning balance, shares at Mar. 31, 2023		25,327,761
Net loss	(10,384)					(10,384)
Stock-based compensation	1,175			1,175
Exercise of stock options	661			661
Exercise of stock options, shares		114,854
Vesting of restricted stock units, shares		5,000
Change in redemption value of share awards in NQDC plan	(467)			(467)
Other comprehensive gain (loss)	101				101
Ending Balance at Jun. 30, 2023	$ 68,647	$ 3	$ (892)	$ 343,769	$ 7,959	$ (282,192)
Ending Balance, shares at Jun. 30, 2023		25,447,615

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flow from operating activities:
Net loss	$ (19,604,000)	$ (15,724,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	281,000	300,000
Stock-based compensation	3,783,000	4,346,000
Non-cash lease expense	331,000	341,000
Loss on fixed asset disposal	3,000
Patent impairment loss	4,000
Remeasurement and foreign currency transaction (gain)/loss	4,000	(39,000)
Excess and obsolete inventory related charges	68,000	158,000
BARDA deferred costs	(64,000)	(64,000)
Contract cost amortization	170,000	169,000
Provision for doubtful accounts	202,000	10,000
Amortization of (premium)/discount of marketable securities	(621,000)	83,000
Non-cash changes in the fair value of NQDC plan	937,000
Changes in operating assets and liabilities:
Trade and other receivables	(2,440,000)	(777,000)
BARDA receivables	456,000	(29,000)
Prepaids and other current assets	(295,000)	205,000
Inventory	(1,003,000)	(52,000)
Operating lease liability	(344,000)	(349,000)
Corporate-owned life insurance asset	(681,000)
Other long-term assets	(164,000)	(467,000)
Accounts payable and accrued expenses	747,000	(179,000)
Accrued wages and fringe benefits	(422,000)	(1,178,000)
Current non-qualified deferred compensation liability	794,000
Other current liabilities	229,000	105,000
Non-qualified deferred compensation plan liability	(221,000)
Contract liabilities	(324,000)	(139,000)
Other long-term liabilities		403,000
Net cash used in operations	(18,174,000)	(12,877,000)
Cash flows from investing activities:
Purchase of marketable securities	(7,633,000)	(32,975,000)
Maturities of marketable securities	45,388,000	25,440,000
Purchase of plant and equipment	(583,000)	(278,000)
Patent filing fees	(22,000)	(32,000)
Net cash provided/(used) in investing activities	37,150,000	(7,845,000)
Cash flow from financing activities:
Proceeds from exercise of stock options	342,000	1,000
Net cash provided by financing activities	342,000	1,000
Effect of foreign exchange rate on cash and restricted cash	3,000	(52,000)
Net increase/(decrease) in cash and cash equivalents and restricted cash	19,321,000	(20,773,000)
Cash and cash equivalents and restricted cash beginning of the period	18,164,000	55,712,000
Cash and cash equivalents and restricted cash end of the period	37,485,000	34,939,000
Supplemental Disclosure of Cash Flow Information
Income taxes paid during the period	44,000	17,000
Interest paid during the period	11,000	$ 4,000
Plant and equipment purchases not yet paid	115,000
Exercise of stock options not yet paid	$ 490,000

The Company

The Company	6 Months Ended
	Jun. 30, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company	1. The Company Nature of the Business AVITA Medical, Inc. and its subsidiaries (collectively, “ AVITA Medical ”, or “ Company ”), is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The Company's RECELL® System technology platform harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. In September 2018, the United States Food & Drug Administration (“ FDA ”) granted premarket approval (“ PMA ”) to the RECELL System for use in the treatment of acute thermal burns in patients eighteen years and older. Following receipt of the original PMA, the Company commenced commercialization of the RECELL System in January 2019 in the United States. In June 2021, the FDA approved expanded use of the RECELL System in combination of meshed autografting for acute full-thickness thermal wounds in pediatric and adult patients. In February 2022, the FDA approved a PMA supplement for the RECELL Autologous Cell Harvesting Device, an enhanced ease-of-use device aimed at providing clinicians a more efficient user experience and simplified workflow. On June 7, 2023, the FDA approved a PMA supplement for full-thickness skin defects based on results of the Company's pivotal trial for soft tissue repair and reconstruction. Following this approval, the Company commenced a commercial launch on June 8, 2023. On June 16, 2023, the FDA approved a PMA application for the repigmentation of stable depigmented vitiligo lesions. The Company plans to commence a full commercial launch following the expected receipt of in-office reimbursement for the use of RECELL in the physician office setting, which the Company anticipates in 2025. Additionally, on June 29, 2023, the Company submitted a PMA supplement to the FDA for its automated cell disaggregation device, RECELL GO™. RECELL GO maintains the FDA Breakthrough Device designation from predecessor devices. In February 2019, the Company entered into a collaboration with COSMOTEC Company Ltd (" COSMOTEC "), an M3 Group company, to market and distribute the RECELL System in Japan. Under the terms of the agreement, AVITA Medical will supply the RECELL product, and COSMOTEC will be the sole distributor of the product in Japan. The Company worked with COSMOTEC to advance its application for approval of the RECELL System in Japan pursuant to Japan’s Pharmaceuticals and Medical Devices Act (“ PMDA ”). In February 2022, COSMOTEC’s application for regulatory approval was approved by the PMDA with labeling for burns only. In September 2022, COSMOTEC commercially launched RECELL in Japan following Japan’s Ministry of Health, Labor, and Welfare approval of reimbursement pricing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP ”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “ SEC ”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2022 filed with the SEC on February 23, 2023 and the Australian Securities Exchange (" ASX ") on February 24, 2023 (the “Annual Report" ). There have been no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K that have had a material impact on the Company’s Consolidated Financial Statements. See the summary of the Company’s significant accounting policies set forth in the notes to its Consolidated Financial Statements included in the Annual Report. Principles of Consolidation The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. Reclassification of prior year presentation Certain prior year amounts within Other current liabilities have been reclassified to Current non-qualified deferred compensation liability, in the Consolidated Balance Sheets for consistency with current period presentation. These reclassifications had no effect on the reported results of operations or financial position. Recent Accounting Pronouncements No new accounting standards were adopted during the three-months and six-months ended June 30, 2023. The Company considers the applicability and impact of recent Accounting Standard Updates (" ASUs ") issued by the Financial Accounting Standards Board (" FASB "). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company's Consolidated Financial Statements. Use of Estimates The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, stock-based compensation, and the stand-alone selling price for the Biomedical Advanced Research and Development Authority ( "BARDA" ) contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts. Foreign Currency Translation and Foreign Currency Transactions The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in Other comprehensive gain (loss) in Stockholders’ Equity. Gains and losses resulting from foreign currency transactions are included in General and administrative expenses in the Consolidated Statement of Operations. Amounts for the three-months ended June 30, 2023 were insignificant, and for the three-months ended June 30, 2022, the Company had a gain of $ 69,000 . Gains and losses resulting from foreign currency transactions were a gain of $ 11,000 and gain of $ 47,000 for the six-months ended June 30, 2023 and 2022, respectively. The Company’s non-operating subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements, and foreign currency transactions are included in General and administrative expenses in the Consolidated Statement of Operations. During the three-months ended June 30, 2023 and 2022, the Company recorded a loss of $ 6,000 and a gain of $ 7,000 , respectively. During the six-months ended June 30, 2023 and 2022, the Company recorded a loss of $ 15,000 and a loss of $ 8,000 , respectively Comprehensive Loss The components of comprehensive loss consist of net loss, foreign currency translation adjustments from the Company's subsidiaries not using the U.S. dollar as their functional currency and unrealized gains and losses in investments available-for-sale. The Company did not have reclassifications from other comprehensive loss to net loss during the three-months and six-months ended June 30, 2023 and 2022. Revenue Recognition The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standard Codification (“ ASC ”) Topic 606 , Revenue Recognition , the Company performs the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations 5. Recognize revenue when/as performance obligation(s) are satisfied In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. Once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised with each contract, determines whether those are performance obligations and the related transaction price. The Company then recognizes the sale of goods based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company’s revenue consists primarily of the sale of the RECELL System to hospitals, treatment centers, COSMOTEC and to BARDA (collectively, “ customers ”), predominately in the United States. The Company evaluated the BARDA contract and concluded that a portion of the arrangement, such as the procurement of the RECELL system and the emergency preparedness, represents a transaction with a customer and as such are in the scope of ASC 606 . Amounts received from BARDA for the research and development of the Company’s product are classified as BARDA income in the Consolidated Statements of Operations and are accounted for under IAS 20 by analogy. For further details refer to BARDA Income and Receivables below. Revenues for commercial customers (hospitals, treatment centers and COSMOTEC) are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. For the Company’s contracts that have an original duration of one year or less, the Company elected the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfillment costs such as commissions and shipping and handling expenses as incurred. For revenues related to the BARDA contract within the scope of ASC 606 , the Company identified two performance obligations: (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services. Under this contract the Company promises to procure the product through a vendor management inventory arrangement and to stand ready to provide emergency deployment services related to the product. Emergency preparedness services include procuring necessary storage containers, housing, and maintaining the containers (and product), and providing shipping and handling services in the event of an emergency situation. This stand ready obligation is a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, over time as services are consumed. The total transaction price for the portion of the BARDA contract that is within the scope of ASC 606 was determined to be $ 9.2 million. The transaction price was allocated on a stand-alone selling price basis as follows: $ 7.6 million to the procurement of the RECELL product, which is classified as Revenues when recognized in the Consolidated Statements of Operations and $ 1.6 million to the emergency deployment services which is classified as Revenues when recognized in the Consolidated Statements of Operations. The $ 1.6 million for emergency deployment includes variable consideration which is deemed immaterial to the contract as a whole. The Company estimated the stand-alone selling price of the procurement of the RECELL product based on historical pricing of the Company’s product at the initial execution of the contract. The Company estimated the stand-alone selling price of the emergency deployment services performed based on the Company’s projected cost of providing the services plus an applicable profit margin as denoted in the contract. The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. The product procurement performance obligation is satisfied at a point in time, upon transfer of control of the product. As such, the related revenue for these performance obligations is recognized at a point in time as Revenue within the Company’s Consolidated Statement of Operations. In addition to guidance under ASC 606 , the Company recognizes revenue from the sales of RECELL product to BARDA for placement into vaccine stockpiles in accordance with SEC Interpretation , Commission Guidance regarding Accounting for Sale of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS). Under this guidance, revenue is recognized when product is placed in the BARDA vendor-managed inventory (" VMI ") as control of the product has been transferred to the customer at the time of delivery to the VMI. RECELL units that have been delivered to BARDA have a product replacement obligation at no cost to BARDA due to the product’s limited shelf-life. The estimated cost of the expired inventory over the term of the contract is recognized on a per unit basis at the time of delivery. The liability is released upon replacement of the product along with a corresponding reduction to inventory. The emergency preparedness services performance obligation is satisfied over time. Revenue for the emergency deployment will be recognized on a straight-line basis during the term of the contract as services are consumed over time. Services recognized are included in Revenues within the Consolidated Statements of Operations. Contract costs to fulfill the performance obligations are incremental and expected to be recovered are capitalized and amortized on a straight-line basis over the term of the contract. Contract costs are included in Prepaids and other current assets in the Consolidated Balance Sheets. For further details refer to Note 5. Contract Liabilities The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30 - 90 days , and do not include a financing component. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. For further details refer to Note 5. Cost of Sales Cost of sales related to products includes costs to manufacture or purchase, package, and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized. Cash and Cash Equivalents Cash and cash equivalents consist of cash held at deposit institutions and cash equivalents. Cash equivalents consist of short-term highly liquid investments with original maturities of three months or less from the date of purchase and consist primarily of money market funds. The Company holds cash at deposit institutions in the amount of $ 5.8 million and $ 4.1 million, of which $ 697,000 and $ 737,000 is denominated in foreign currencies in foreign institutions as of June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company held cash equivalents in the amount of $ 31.7 million and $ 14.1 million, respectively. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, BARDA receivables and other receivables. As of June 30, 2023 and December 31, 2022, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits and subject to the risk of bank failure. As of June 30, 2023 no single commercial customer accounted for more than 10 % of net accounts receivable. As of December 31, 2022, one commercial customer accounted for more than 10 % of total net accounts receivable. For the three-months and six-months ended June 30, 2023 and 2022, no single customer accounted for more than 10 % of revenues. BARDA revenue for emergency deployment accounted for less than 1 % of total revenues for the three-months and six-months ended June 30, 2023 and 2022. BARDA receivables for emergency preparedness services accounted for 4 % and 2 % of total BARDA receivables as of June 30, 2023 and December 31, 2022, respectively. See table below for breakdown of BARDA receivables (in thousands). As of June 30, 2023 December 31, 2022 BARDA procurement and emergency preparedness services $ 16 $ 16 BARDA expense reimbursements 426 882 Total $ 442 $ 898 Marketable Securities We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date . Classification is determined at the time of purchase and re-evaluated each balance sheet date. Short-term marketable securities represent investment of cash available for current operations. All marketable securities, which consist of corporate debt securities, asset backed securities, U.S government agency obligations, U.S treasury and commercial paper are denominated in U.S. dollars, have been classified as “available-for-sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in Other comprehensive income (loss) and reported as a separate component of Stockholders' Equity until realized. Realized gains and losses on marketable securities are included in Other income in the accompanying Consolidated Statements of Operations. The cost of any marketable securities sold is based on the specific identification method. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in Other income in the accompanying Consolidated Statements of Operations. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the maximum final maturity from the date of purchase is thirty-seven months . If necessary, the Company will recognize an allowance for credit losses on available-for-sale debt securities on an individual basis and will no longer consider other-than-temporary impairment or immediately reduce the cost basis of the investment, provided that it is more likely than not that the security will be held to recovery or maturity. Further, the Company will recognize any improvements in estimated credit losses on available-for-sale debt securities immediately in earnings and reduce the existing allowance for credit losses. The Company will disaggregate its available-for-sale debt securities into the following categories: commercial paper, corporate debt, government and agency securities, asset backed securities and money market funds. The Company’s corporate bonds are comprised of predominantly high-grade corporate bonds while its government and agency securities are U.S. treasury bonds, and U.S. agency bonds. The Company has analyzed both corporate bonds and government and agency securities and identified that both types of securities have similar risk characteristics in that they are traded infrequently and have contractual interest rates and maturity dates. To evaluate for impairment, management reviews credit rating changes, securities trends, interest rate movements and unrealized loss at the security level of the Company’s available-for-sale debt securities. If any of these give rise to a potential credit concern, the Company performs a discounted cash flow analysis to determine the credit portion of the impairment. The discounted cash flow analysis will be performed either internally or through the assistance of a qualified third party. Once the credit component of the impairment is determined, the Company will record the impaired amount as an allowance to the available-for-sale debt securities balance and as a charge to Other income in the accompanying Consolidated Statements of Operations, not to exceed the amount of the unrealized loss. The Company assesses expected credit losses at the end of each reporting period and adjusts the allowance through Other income. BARDA Income and Receivables The Company was awarded the BARDA grant in September 2015. Under this grant, BARDA supported the Company’s research and development for the Company’s product, including the U.S. clinical regulatory program targeted towards FDA PMA, compassionate use programs, clinical and health economics research, and U.S. pediatric burn programs. Currently, the BARDA contract is supporting the Company's clinical trial in soft-tissue reconstruction, which led to the full-thickness skin defect indication. Consideration received under the BARDA grant is earned and recognized under a cost-plus-fixed-fee arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs and a fixed-fee earned. Billings under the contracts are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, general and administrative expenses and a fixed fee. The Company has concluded that grants under the BARDA grant are not within the scope of ASC 606 , as they do not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition also does not apply, as the Company is a business entity, and the grants are with governmental agencies or units. With respect to the BARDA grant, we considered the guidance in IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy. BARDA income and related receivables are recognized when there is reasonable assurance that the grant will be received, and all attaching conditions have been complied with. When the grant relates to an expense item, the grant received is recognized as income over the period when the expense was incurred. Leases The Company has operating leases for c orporate office space, manufacturing and a warehouse facility. The Company’s operating leases have remaining lease terms of one year to three years , so me of which include options to renew the lease. At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the Consolidated Balance Sheets. Right-of-use (“ ROU ”) assets represent the Company’s right to control an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an explicit rate, the Company used its incremental borrowing rate (“ IBR ”) based on the information available at the commencement date in determining the discount rate used to present value lease payments. In determining the IBR, the Company considered its credit rating and current market interest rates. The IBR used approximates the interest that the Company would be required to pay for a collateralized loan over a similar term. The Company’s leases typically do not include any residual value guarantees or asset retirement obligations. The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. Lease expense is recognized on a straight-line basis over the lease term and is primarily included in General and administrative expenses in the accompanying Consolidated Statements of Operations. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all underlying asset classes. Some leases require variable payments for common area maintenance, property taxes, parking, insurance and other variable costs. The variable portion of lease payments is not included in operating lease assets or liabilities. Variable lease costs are expensed when incurred. Stock-Based Compensation The Company records compensation expense for stock options and restricted stock units (" RSU ") based on the fair market value of the awards on the date of grant. The fair value of stock-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is evaluated based on the number of shares ultimately expected to vest, evaluated each reporting period and based on management’s expectations regarding the relevant performance criteria. The Black-Scholes option pricing model and Monte Carlo Simulation are used to estimate the fair value of the time-based and performance-based options, respectively. Under ASU 2016-09 , Compensation – Stock Compensation (“ASC 718”) Improvements to Employee Share-Based Payment Accounting , the Company elected to account for forfeitures as they occur. The following assumptions were used in the valuation of stock options. • Expected volatility – determined using the average of the historical volatility using daily intervals over the expected term and the derived volatility using the longest term available of 12 months. • Expected dividends - based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future • Expected term – the expected term of the Company’s stock options for tenure only vesting has been determined utilizing the “simplified” method as described in the SEC’s Staff Accounting Bulletin No. 107 relating to share-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history of awards granted, with the first plan being established in 2016 which was primarily used for executive awards. Further, the Company does not have sufficient history of exercises in the U.S. market given the Company’s redomiciliation from Australia to the United States in 2020. The expected term of options with a performance condition or market condition was set to the contractual term of 10 years. The contractual term was used for options with a performance or market condition as these are primarily awarded to executives and the Company assumes that they will hold them longer than rank and file employees. • Risk-free interest rate – the risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award. Non-Qualified Deferred Compensation Plan Liability and Corporate-Owned Life Insurance Asset The Company’s non-qualified deferred compensation plan (the " NQDC plan "), which became effective in October 2021, allows highly compensated key employees to elect to defer a portion of their salary, bonus and RSU awards to later years. Management determined that the cash deferrals under the NQDC plan shall be accounted for similarly to a defined benefit plan under ASC 715 , Compensation – Retirement Benefits , and should follow accounting treatment that is similar to a cash balance plan. Management determined that the employee portion and employer portion of the deferred compensation should be recognized as a compensation expense with a corresponding credit to deferred compensation liability. The matching contribution will be accrued over the vesting period of two years with 25 % vesting in the first year and 75 % vesting in the second year. Employees aged 55 or older immediately vest in employer matching contributions. The change in the liability between each reporting period is accounted for as compensation expense with a corresponding adjustment to deferred compensation liability. Upon distribution, the Company will record the distribution as a decrease to deferred compensation liability with a corresponding credit to cash. The Company funds the NQDC plan through a Corporate-Owned Life Insurance ( “COLI” ). Per the ASC 325-30-25-1A, Investments – Other , COLI is recorded as an asset on the Consolidated Balance Sheets as it does not meet the definition of a plan asset under ASC 715 . The Company invests in COLI policies relating to its deferred compensation plan. Investments in COLI policies are recorded at their cash surrender values as of each balance sheet date. Changes in the cash surrender value during the period are recorded as a gain or loss in the Consolidated Statements of Operations in Other income. Rabbi Trust During April 2022, the Company established a rabbi trust for a select group of participants in which share awards granted under the 2020 Omnibus Incentive Plan ( “2020 Plan” ) and deferred under the NQDC plan may be deposited. In addition to the deferral of shares, the rabbi trust holds the assets in the COLI for the NQDC plan. The rabbi trust is an irrevocable trust, and no portion of the trust fund may be used for any purpose other than the delivery of those assets to the participants. The assets held in the rabbi trust are subject to the claims of our general creditors in the event of bankruptcy or insolvency. The value of the assets of the rabbi trust is consolidated into our financial statements. The NQDC plan permits diversification of vested shares (common stock) into other equity securities subject to a six-month and one day holding period subsequent to vesting. Per ASC 710-10-25-15 , accounting for deferred common stock will be under plan type C or D. Accounting will depend on whether or not the employee has diversified the common stock. Under Plan type C, diversification is permitted but the employee has not diversified. Under plan type D, diversification is permitted, and the employee has diversified. For common stock that have not been diversified, the employer stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Company common stock held by the NQDC plan. The common stock will be recorded at the fair value of the stock at the time it vested, subsequent changes in the value of the common stock will not be recognized. The deferred compensation obligation is measured independently at fair value of the common stock with a corresponding charge or credit to compensation cost. The fair value is calculated as the product of the common stock and the closing price of the stock each reporting period. Under plan type D, the accounting for the assets held by the rabbi trust is subject to the accounting pronouncements under applicable GAAP for each asset type. As diversified common stock will be invested in mutual funds, assets held by the rabbi trust will be subject to accounting under ASC 321 - Investments - Equity Securities . The deferred compensation obligation is measured independently at fair value of the underlying assets. As of June 30, 2023, none of the deferred common stock has been diversified. Non-Qualified Deferred Compensation Stock Awards In accordance with ASC 718, Compensation — Stock Compensation , the deferred RSU awards under the NQDC plan are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. As the plan permits diversification, presentation outside of permanent equity in accordance with ASR 268, Redeemable Preferred Stock is appropriate. The redemption amounts are based on the vested percentage and are recorded outside of equity as Non-qualified deferred compensation share awards on the Consolidated Balance Sheets. Deferred awards will be presented outside of permanent equity until the awards are vested. For further details refer to Note 17.

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2023
Available For Sale Securities [Abstract]
Marketable Securities	3. Marketable Securities The following table summarizes the amortized cost and estimated fair values of debt securities available-for-sale: As of June 30, 2023 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 30,669 $ - $ - $ 30,669 U.S. Treasury securities 999 1 - 1,000 Total cash equivalents $ 31,668 $ 1 $ - $ 31,669 Current marketable securities: U.S. Treasury securities $ 23,227 $ - $ ( 69 ) $ 23,158 Commercial paper 2,311 - - 2,311 Corporate debt securities 1,422 - ( 5 ) 1,417 U.S. Government agency obligations 1,681 - ( 5 ) 1,676 Total current marketable securities $ 28,641 $ - $ ( 79 ) $ 28,562 Long-term marketable securities: Asset backed securities $ 2,759 $ 2 $ ( 7 ) $ 2,754 Total long-term marketable securities $ 2,759 $ 2 $ ( 7 ) $ 2,754 As of December 31, 2022 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 14,089 $ - $ - $ 14,089 Current marketable securities: U.S. Treasury securities $ 43,092 $ 1 $ ( 393 ) $ 42,700 Commercial paper 12,743 - - 12,743 Corporate debt securities 3,865 - ( 23 ) 3,842 U.S. Government agency obligations 1,901 - ( 8 ) 1,893 Total current marketable securities $ 61,601 $ 1 $ ( 424 ) $ 61,178 Long-term marketable securities: Asset backed securities $ 3,568 $ 7 $ ( 3 ) $ 3,572 U.S. Treasury securities 2,416 - ( 6 ) 2,410 U.S. Government agency obligations 949 - ( 1 ) 948 Total long-term marketable securities $ 6,933 $ 7 $ ( 10 ) $ 6,930 The maturities of debt securities available-for-sale are summarized in the following table using contractual maturities. Actual maturities may differ from contractual maturities due to obligations that are called or prepaid. As of June 30, 2023 As of December 31, 2022 (in thousands) Amortized Carrying Amortized Carrying Due in one year or less $ 28,641 $ 28,562 $ 61,601 $ 61,178 Due after one year through three years $ 2,759 $ 2,754 $ 6,933 $ 6,930 Gross unrealized gains and losses on the Company’s marketable securities were an unrealized gain of $ 3,000 and an unrealized loss of $ 86,000 as of June 30, 2023, which resulted in a net unrealized loss of $ 83,000 . Gross unrealized gains and losses on the Company’s marketable securities were an unrealized gain of $ 8,000 and an unrealized loss of $ 434,000 as of December 31, 2022, which resulted in a net unrealized loss of $ 426,000 . As of June 30, 2023, and December 31, 2022, the Company did no t recognize credit losses. The Company has accrued interest income of $ 168,000 as of June 30, 2023, and December 31, 2022, in Prepaids and other current assets.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date. Level 2: Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Inputs are unobservable inputs for the asset or liability. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: As of June 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 30,669 $ - $ - $ 30,669 U.S. Treasury securities - 1,000 - 1,000 Total Cash equivalents $ 30,669 $ 1,000 $ - $ 31,669 Current marketable securities: U.S. Treasury securities $ - $ 23,158 $ - $ 23,158 Commercial paper - 2,311 - 2,311 Corporate debt securities - 1,417 - 1,417 U.S. Government agency obligations - 1,676 - 1,676 Total current marketable securities $ - $ 28,562 $ - $ 28,562 Long-term marketable securities: Asset backed securities $ - $ 2,754 $ - $ 2,754 Total long-term marketable securities $ - $ 2,754 $ - $ 2,754 Total marketable securities and cash equivalents $ 30,669 $ 32,316 $ - $ 62,985 As of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 14,089 $ - $ - $ 14,089 Current marketable securities: U.S. Treasury securities - 42,700 - 42,700 Commercial paper - 12,743 - 12,743 Corporate debt securities - 3,842 - 3,842 U.S. Government agency obligations - 1,893 - 1,893 Total current marketable securities $ - $ 61,178 $ - $ 61,178 Long-term marketable securities: Asset backed securities $ - $ 3,572 $ - $ 3,572 U.S. Treasury securities - 2,410 - 2,410 U.S. Government agency obligations - 948 - 948 Total long-term marketable securities $ - $ 6,930 $ - $ 6,930 Total marketable securities and cash equivalents $ 14,089 $ 68,108 $ - $ 82,197 The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of commercial paper, U.S. Government agency obligations, corporate debt securities, asset backed securities and U.S Treasury securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of June 30, 2023 and December 31, 2022, the Company had no investments that were measured using unobservable (Level 3) inputs. There were no transfers between fair value measurement levels as of June 30, 2023 or December 31, 2022.

Revenues

Revenues	6 Months Ended
	Jun. 30, 2023
Revenue Performance Obligation [Abstract]
Revenues	5. Revenues Revenues The Company’s revenue consists of sale of the RECELL System to hospitals, treatment centers and COSMOTEC (“ commercial customers ”) and to BARDA (collectively “ customers ”), predominately in the United States. In addition, the Company records service revenue for the emergency preparedness services provided to BARDA. Performance Obligations For commercial contracts, we identified the hospital, treatment center, or COSMOTEC as the customer in Step 1 of the 5-step model of ASC 606 and have determined a contract exists with those customers. As these contracts typically have a single performance obligation (i.e., product delivery), no allocation of the transaction price is required in Step 4 of the model. Control of the product is transferred to the customer at a point in time, at the point in time at which the goods are either shipped or delivered to the customers’ facilities, depending on the terms of the contract. The transaction price is stated within the contract and is therefore fixed consideration. The transaction price does not include the sales tax that is imposed by governmental authorities. For the contract with BARDA, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services. The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. The product procurement performance obligation is satisfied at a point in time, upon transfer of control of the product. RECELL units that have been delivered to BARDA have a product replacement obligation at no cost to BARDA due to the product’s limited shelf-life. The estimated cost of the expired inventory over the term of the contract is recognized on a per unit basis at the time of delivery. The liability is released upon replacement of the product along with a corresponding reduction to inventory. The Company has estimated deferred cost of approximately $ 130,000 and $ 194,000 as of June 30, 2023 and December 31, 2022, respectively, for the rotation cost of the product and are included Other current liabilities in the Consolidated Balance Sheets. The emergency preparedness services performance obligation is satisfied over time. Revenue for the emergency deployment will be recognized on a straight-line basis during the term of the contract as services are consumed over time. Services recognized for the three-months ended June 30, 2023 and 2022, were $ 67,000 and $ 93,000 , respectively. Services recognized for the six-months ended June 30, 2023 and 2022, were $ 160,000 and $ 186,000 , respectively. Services are included in Revenues within the Consolidated Statements of Operations. Contract costs to fulfill the performance obligation that are incremental and are expected to be recovered are capitalized and amortized on a straight-line basis over the term of the contract. As of June 30, 2023 and December 31, 2022, contract costs of $ 126,000 and $ 252,000 are included in Prepaids and other current assets in the Consolidated Balance Sheets. Remaining Performance Obligations Revenues from remaining performance obligations are calculated as the dollar value of the remaining performance obligations on executed contracts. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to the Company’s existing customer agreements is $ 557,000 and $ 698,000 as of June 30, 2023 and December 31, 2022, respectively. Approximately $ 149,000 as of June 30, 2023 and $ 274,000 as of December 31, 2022, of the total balance relates to our July 2020 contract with BARDA for the purchase, delivery and storage of RECELL Systems for emergency response preparedness for a period of three years. The Company expects to recognize these amounts as services are provided to BARDA. We are contracted to manage this inventory of product until the federal government requests shipment or at contract termination on December 31, 2023. The remaining balance of $ 408,000 and $ 424,000 as of June 30, 2023 and December 31, 2022, respectively, relate to our contract with COSMOTEC. The Company expects to recognize these amounts as revenue on a straight-line basis over the term of the contract with COSMOTEC. Variable Consideration The Company evaluates its contracts with customers for forms of variable consideration, which may require an adjustment to the transaction price based on their estimated impact. For commercial customers, revenue from the sale of goods is recognized net of volume discounts. The Company uses the expected value method when estimating variable consideration. Revenue is only recognized to the extent that it is probable that a significant reversal will not occur. Variable consideration under the BARDA contract is not material to the Consolidated Financial Statements. Contract Assets and Contract Liabilities Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of the period ended June 30, 2023 and December 31, 2022, the Company does no t have any contract assets. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. The Company had $ 557,000 and $ 698,000 of contract liabilities as of June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, a total of $ 183,000 and $ 0 , respectively, was included in Other current liabilities and $ 374,000 and $ 698,000 , respectively, in Contract liabilities in the Consolidated Balance Sheets. The balance relates to the unsatisfied performance obligation for emergency preparedness under the BARDA and amounts received from COSMOTEC. The Company recognized $ 67,000 and $ 93,000 of revenue from BARDA for amounts included in the beginning balance of contract liabilities for the three-months ended June 30, 2023 and 2022, respectively, and $ 160,000 and $ 186,000 for the six-months ended June 30, 2023 and 2022, respectively. The Company recognized $ 8,000 and $ 17,000 of revenue from COSMOTEC for amounts included in the beginning balance of contract liabilities for the three-months and six-months ended June 30, 2023. The Company did no t recognize any the amounts of revenue included in the beginning balance of contract liabilities for the three-months and six-months ended June 30, 2022. Cost to Obtain and Fulfill a Contract Commercial contract fulfillment costs include commissions and shipping expenses. The Company has opted to immediately expense the incremental cost of obtaining a contract when the underlying related asset would have been amortized over one year or less. The Company generally does not incur costs to obtain new contracts. BARDA Contract Costs Cost to fulfill the BARDA emergency preparedness performance obligation, which primarily consist of billed costs to BARDA incurred in connection with the emergency deployment services, are incremental and expected to be recovered. Costs are capitalized and amortized on a straight-line basis over the term of the contract. As of June 30, 2023, and December 31, 2022, the Company had $ 126,000 and $ 252,000 of contracts costs included in Prepaids and other current assets in the Consolidated Balance Sheets. Amortization expense related to deferred contract costs was $ 85,000 and $ 84,000 for the three-months ended June 30, 2023 and 2022, respectively, and $ 170,000 and $ 169,000 for the six-months ended June 30, 2023 and 2022, respectively, and are classified as Cost of sales on the accompanying Consolidated Statements of Operations. There was no impairment loss in relation to deferred contract costs during the three-months and six-months ended June 30, 2023, and 2022. Disaggregated Revenue The Company disaggregates revenue from contracts with customers into geographical regions and by customer type. As noted in the segment footnote, the Company’s business consists of one reporting segment. A reconciliation of disaggregated revenue by geographical region and customer type is provided in Segment Note 11.

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	6. Leases During February 2023, the Company remeasured the lease liability for an office lease due to a change in the lease term. As a result of the remeasurement of the lease liability, there was an increase of approximately $ 1.1 million to the operating lease ROU assets and operating lease liabilities. There was no impact on earnings as a result of the lease modification. The following table sets forth the Company’s operating lease expenses which are included in General and administrative expenses in the Consolidated Statements of Operations (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Operating lease cost $ 197 $ 194 $ 395 $ 388 Variable lease cost 13 13 26 25 Total lease cost $ 210 $ 207 $ 421 $ 413 Supplemental cash flow information related to Operating leases for the three-months and six-months ended June 30, 2023 and 2022 was as follows (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 205 $ 199 $ 410 $ 397 Supplemental balance sheet information, as of June 30, 2023 and December 31, 2022, related to operating leases was as follows (in thousands, except for Operating lease weighted average remaining lease term and operating lease weighted average discount rate): As of June 30, 2023 December 31, 2022 Reported as: Operating lease right-of-use assets $ 1,651 $ 851 Total right-of-use assets $ 1,651 $ 851 Other current liabilities : Operating lease liabilities, short-term $ 656 $ 612 Operating lease liabilities, long term 1,047 306 Total operating lease liabilities $ 1,703 $ 918 Operating lease weighted average remaining lease term (years) 2.73 1.44 Operating lease weighted average discount rate 7.93 % 6.71 % As of June 30, 2023, maturities of the Company’s operating lease liabilities are as follows (in thousands): Operating Leases Remainder of 2023 $ 345 2024 741 2025 441 2026 377 Total lease payments 1,904 Less imputed interest ( 201 ) Total operating lease liabilities $ 1,703 As of June 30, 2023, the Company had an office space lease that subsequently commenced July 2023 for a term of 5 -years with an average monthly rent of approximately $ 25,000 .

Inventory

Inventory	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory	. Inventory The composition of inventory is as follows (in thousands): As of June 30, 2023 December 31, 2022 Raw materials $ 1,882 $ 1,131 Work in process 491 384 Finished goods 685 610 Total inventory $ 3,058 $ 2,125 The Company has reduced the carrying value of its inventories to reflect the lower of cost or net realizable value. Charges for estimated excess and obsolescence are recorded in Cost of sales in the Consolidated Statements of Operations and were $ 2,000 and $ 61,000 for the three-months ended June 30, 2023 and 2022, respectively, and $ 68,000 and $ 158,000 for the six-months ended June 30, 2023 and 2022, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	8. Intangible Assets The composition of intangible assets, net is as follows (in thousands): As of June 30, 2023 As of December 31, 2022 Weighted Gross Accumulated Net Gross Accumulated Net Patent 1 3 $ 17 $ ( 16 ) $ 1 $ 17 $ ( 16 ) $ 1 Patent 2 13 138 ( 33 ) 105 137 ( 28 ) 109 Patent 3 14 195 ( 46 ) 149 194 ( 39 ) 155 Patent 5 19 98 ( 9 ) 89 89 ( 6 ) 83 Patent 6 20 44 ( 5 ) 39 43 ( 4 ) 39 Patent 7 13 2 - 2 2 - 2 Patent 8 19 10 ( 1 ) 9 13 - 13 Patent 10 19 3 - 3 3 - 3 Patent 11 19 6 ( 1 ) 5 6 - 6 Trademarks Indefinite 54 - 54 54 - 54 Total intangible assets $ 567 $ ( 111 ) $ 456 $ 558 $ ( 93 ) $ 465 For the three-months and six-months ended June 30, 2023 the Company recorded an impairment charge of approximately $ 4,000 in General and administrative expenses in the Consolidated Statement of Operations. During the three-months and six-months ended June 30, 2022, the Company did not identify any events or changes in circumstances that indicated that the carrying value of its intangibles may not be recoverable. As such, there was no impairment of intangibles assets recognized for the three-months and six-months ended June 30, 2022. Amortization expense of intangibles included in the Consolidated Statements of Operations were $ 8,000 for the three-months ended June 30, 2023 and 2022, respectively, and $ 17,000 and $ 42,000 for the six-months ended June 30, 2023 and 2022, respectively. The Company expects the future amortization of amortizable intangible assets held at June 30, 2023 to be as follows (in thousands): Estimated Remainder of 2023 $ 17 2024 34 2025 34 2026 34 2027 33 2028 33 Thereafter 217 Total $ 402

Plant and Equipment

Plant and Equipment	6 Months Ended
	Jun. 30, 2023
Property Plant And Equipment [Abstract]
Plant and Equipment	9. Plant and Equipment The composition of property, plant and equipment, net is as follows (in thousands): As of Useful Lives June 30, 2023 December 31, 2022 Computer equipment 3 years $ 889 $ 755 Computer software 3 years 980 871 Construction in progress 423 258 Furniture and fixtures 7 years 616 439 Laboratory equipment 5 years 696 643 Leasehold improvements Lesser of life or lease term 257 257 RECELL moulds 5 years 128 129 Less: accumulated amortization and depreciation ( 2,391 ) ( 2,152 ) Total plant and equipment, net $ 1,598 $ 1,200 Depreciation expense related to plant and equipment was $ 137,000 and $ 129,000 for the three-months ended June 30, 2023 and 2022 respectively, and $ 264,000 and $ 258,000 for the six-months ended June 30, 2023 and 2022, respectively. For the three-months and six-months ended June 30, 2023, the Company recorded an impairment charge of approximately $ 3,000 in General and administrative expenses in the Consolidated Statement of Operations. During the three-months and six-months ended June 30, 2022, the Company did not identify any events or changes in circumstances that indicated that the carrying value of its plant and equipment may not be recoverable. As such, there was no impairment of plant and equipment recognized for the three-months and six-months ended June 30, 2022.

Other Current and Long-Term Ass

Other Current and Long-Term Assets and Liabilities	6 Months Ended
	Jun. 30, 2023
Other Current And Long Term Assets And Liabilities [Abstract]
Other Current and Long-Term Assets and Liabilities	10. Other Current and Long-Term Assets and Liabilities Prepaids and other current assets consisted of the following (in thousands): As of June 30, 2023 December 31, 2022 Prepaid expenses $ 1,375 $ 921 Lease deposits - 110 Accrued investment income 168 168 BARDA contract costs 126 252 Other receivables 525 127 Total prepaids and other current assets $ 2,194 $ 1,578 Prepaid expenses primarily consist of prepaid benefits and insurance. Other long-term assets consisted of the following (in thousands): As of June 30, 2023 December 31, 2022 Long-term lease deposits $ 189 $ 25 Long-term prepaids 96 97 Total other long-term assets $ 285 $ 122 Other current liabilities consisted of the following (in thousands): As of June 30, 2023 December 31, 2022 Operating lease liability $ 656 $ 612 BARDA deferred costs 130 194 BARDA deferred revenue 183 - Other current liabilities 232 184 Total other current liabilities $ 1,201 $ 990

Reporting Segment and Geographi

Reporting Segment and Geographic Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Reporting Segment and Geographic Information	11. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. Long-lived assets are primarily located in the United States as of June 30, 2023, and December 31, 2022, with an insignificant amount located in Australia and the United Kingdom. Revenue by region for the three-months and six-months ended June 30, 2023 and 2022 were as follows (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Revenue: United States $ 10,992 $ 8,278 $ 20,417 $ 15,676 Foreign: Japan 708 - 1,729 - Australia 33 29 95 116 United Kingdom 20 28 62 82 Total $ 11,753 $ 8,335 $ 22,303 $ 15,874 Revenue and cost of sales by customer type for the three-months and six-months ended June 30, 2023 and 2022 were as follows (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Revenue: Commercial sales $ 11,686 $ 8,242 $ 22,143 $ 15,688 BARDA: Services for emergency preparedness 67 93 160 186 Total $ 11,753 $ 8,335 $ 22,303 $ 15,874 Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Cost of sales: Commercial cost $ 2,108 $ 1,302 $ 3,724 $ 3,007 BARDA: Product cost 11 - ( 23 ) ( 12 ) Emergency preparedness service cost 85 84 170 169 Total $ 2,204 $ 1,386 $ 3,871 $ 3,164

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of June 30, 2023 and December 31, 2022, the Company did no t have any outstanding or threatened litigation that would have a material impact on the financial statements.

Common and Preferred Stock

Common and Preferred Stock	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Common and Preferred Stock	13. Common and Preferred Stock The Company’s CHESS Depositary Interests (“ CDIs ”) are quoted on the ASX under the ticker code, “AVH”. The Company’s shares of common stock are quoted on the Nasdaq Capital Market (“ Nasdaq ”) under the ticker code, “RCEL”. One share of common stock on Nasdaq is equivalent to five CDIs on the ASX. The Company is authorized to issue 200,000,000 shares of common stock, par value $ 0.0001 per share, and 10,000,000 shares of preferred stock, par value $ 0.0001 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of June 30, 2023, and December 31, 2022, 25,447,615 and 25,208,436 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding during any period.

Stock-Based Payment Plans

Stock-Based Payment Plans	6 Months Ended
	Jun. 30, 2023
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Payment Plans	14. Stock-Based Payment Plans Overview of Employee Stock-Based Compensation Plans Our former parent company, AVITA Medical Pty Limited, adopted the Employee Share Plan and the Incentive Option Plan (collectively, the “ 2016 Plans ”). Upon completion of the redomiciliation of the Company from Australia to the United States in June 2020 (“ Redomiciliation ”), the 2016 Plans were terminated with respect to future grants and accordingly, there are no more shares available to be issued under the 2016 Plans. In addition, upon completion of the Redomiciliation, the Company had an implicit consolidation or reverse stock split of 100:1 and all share information presented below in relation to the 2016 Plans has been presented on a reverse stock split basis. During November 2020, the Company filed a registration statement on Form S-8 to register a total of 1,750,000 shares of common stock which may be issued pursuant to the terms of the 2020 Plan. During June 2023, the Company filed a registration statement on Form S-8 to register an additional 2,500,000 shares of common stock under the 2020 Plan. The increase in shares available for issuance was a result of the stockholders of AVITA Medical, Inc. approving an amendment to the 2020 Plan on June 6, 2023 at the Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting” ). On December 22, 2021, the Company’s stockholders approved the issuance of options and RSUs to the Board of Directors in accordance with ASX rules. These awards are subject to the vesting and performance conditions as denoted in the individual agreements (collectively, the " 2021 Annual Meeting Awards "). On December 12, 2022, the Company's stockholders approved the issuance of options and RSUs to the Board of Directors and the CEO in accordance with ASX rules. These awards are subject to vesting conditions as denoted in the individual agreements (collectively, the " 2022 Annual Meeting Awards "). On June 6, 2023, the Company's stockholders approved the issuance of options and RSUs to the Board of Directors and the CEO in accordance with ASX rules. These awards are subject to vesting conditions as denoted in the individual agreements (collectively, the " 2023 Annual Meeting Awards "). The 2020 Plan provides for the grant of the following Grants: (a) Incentive Stock Options, (b) Nonstatutory Stock Options, (c) Stock Appreciation Rights, (d) Restricted Stock Grants, (e) Restricted Stock Unit Grants, (f) Performance Grants, and (g) Other Grants. The 2020 Plan will be administered by the Compensation Committee or by the Board acting as the Compensation Committee. Subject to the general purposes, terms and conditions of the 2020 Plan, applicable law and any charter adopted by the Board governing the actions of the Compensation Committee, the Compensation Committee will have full power to implement and carry out the 2020 Plan. Without limitation, the Compensation Committee will have the authority to interpret the plan, approve persons to receive grants, determine the terms and number of shares of the grants, determine vesting and exercisability of grants, and make all other determinations necessary or advisable in connection with the administration of this Plan. The contractual term of stock option awards granted under the 2020 Plan is ten years from the grant date. Unless otherwise specified, the vesting periods of options and RSUs granted under the 2020 Plan are: (i) vest over a three-year or four-year period in equal installments at the end of each year from the date of grant, and /or (ii) subject to other performance criteria and hurdles, as determined by the Compensation Committee. Stock-Based Payment Expenses Stock-based payment transactions are recognized as compensation expense based on the fair value of the instrument on the date of grant. The Company uses the graded-vesting method to recognize compensation expense. Compensation cost is reduced for forfeitures as they occur in accordance with ASU 2016-09 , Simplifying the Accounting for Share-Based Payment. The Company recorded stock-based compensation expense of $ 1.1 million and $ 1.4 million for the three-months ended June 30, 2023 and 2022, respectively, and $ 3.8 million and $ 4.3 million for the six-months ended June 30, 2023 and 2022, respectively. No income tax benefit was recognized in the Consolidated Statements of Operations for stock-based payment arrangements for the three-months and six-months ended June 30, 2023, and 2022. The Company has included stock-based compensation expense as part of operating expenses in the accompanying Consolidated Statements of Operations as follows: Three-Months Ended Six-Months Ended (In thousands) June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Sales and marketing expenses $ 76 $ 285 $ 401 $ 614 General and administrative expenses 818 983 2,908 3,310 Research and development expenses 249 146 474 422 Total $ 1,143 $ 1,414 $ 3,783 $ 4,346 A summary of share option activity as of June 30, 2023, and changes during the period ended is presented below: Service Only Share Options Performance Based Share Options Total Share Options Outstanding shares at December 31, 2022 1,724,252 511,194 2,235,446 Granted 889,193 - 889,193 Exercised ( 116,529 ) ( 30,000 ) ( 146,529 ) Expired ( 59,125 ) ( 178,156 ) ( 237,281 ) Forfeited ( 58,413 ) ( 6,958 ) ( 65,371 ) Outstanding shares at June 30, 2023 2,379,378 296,080 2,675,458 Exercisable at June 30, 2023 720,303 235,896 956,199 Restricted Stock Units Restricted stock units are granted to executives as part of their long-term incentive compensation. RSUs granted to directors as a result of stockholder approval 2021 Annual Meeting, 2022 Annual Meeting and 2023 Annual Meeting are issued pursuant to award agreements between the Company and the holders of such securities. These RSU awards were approved by the Compensation Committee. All RSU awards vest in accordance with the tenure or performance conditions as determined by the Compensation Committee and set out in the contracts between the Company and the holders of such securities. The grant date fair value is determined based on the price of the Company stock price on the date of grant (stock price determined on Nasdaq). A summary of the status of the Company’s unvested RSUs as of June 30, 2023, and changes that occurred during the period is presented below: Unvested Shares Tenure-Based RSUs Performance Total RSUs Unvested RSUs outstanding at December 31, 2022 394,872 65,646 460,518 Granted 57,798 - 57,798 Vested ( 76,900 ) ( 15,750 ) ( 92,650 ) Forfeited ( 39,250 ) ( 7,875 ) ( 47,125 ) Unvested RSUs outstanding at June 30, 2023 336,520 42,021 378,541 2021 Annual Meeting Awards Awards to non-executive members of the Board of Directors ("Director awards") under the 2021 Annual Meeting Awards The Director awards that were granted in 2021 consist of an aggregate 68,600 options and RSUs as follows: • 41,400 tenure-based options and RSUs ( 15,300 options and 26,100 RSUs) vesting 12 months from the grant date. o Includes 6,900 tenure-based options and RSUs ( 4,350 RSUs and 2,550 options) were granted to each of the six non-executive board members based on the vesting terms detailed above. • 27,200 tenure-based options and RSUs ( 9,850 options and 17,350 RSUs) vesting on the first, second and third anniversary of the grant date in equal amounts (i.e., 1/3 of the RSUs and options will vest on each anniversary of the grant date, being on December 22 of each relevant year). o Includes 13,600 tenure-based options and RSUs ( 8,675 RSUs and 4,925 options) were granted to Jan Stern Reed and James Corbett as an initial grant in connection with their appointment to the Board of Directors. 2022 Annual Meeting Awards Awards to the CEO under the 2022 Annual Meeting Awards On December 12, 2022, the CEO was issued an aggregate 226,296 options with 25 % of those options vesting annually commencing on September 28, 2023. Non-Executive Director awards under the 2022 Annual Meeting Awards The Director awards consist of an aggregate 71,936 options and RSUs ( 21,580 options and 50,356 RSUs) vesting 12 months from the grant date. • 17,984 tenure-based options and RSUs ( 12,589 RSUs and 5,359 options) granted to each of the four non-executive board members based on the vesting terms detailed above. 2023 Annual Meeting Awards Awards to the CEO under the 2023 Annual Meeting Awards On June 6, 2023, the CEO was issued an aggregate 100,000 options with 33.3 % of those options vesting annually commencing on June 6, 2024. Non-Executive Director awards under the 2023 Annual Meeting Awards The Director awards consist of an aggregate 82,566 options and RSUs as follows: • 52,926 tenure-based options and RSUs ( 15,876 options and 37,050 RSUs) vesting 12 months from the grant date. o 8,821 tenure-based options and RSUs ( 2,646 options and 6,175 RSUs) granted to each of the six non-executive board members based on the vesting terms detailed above. • 29,640 tenure-based options and RSUs ( 8,892 options and 20,748 RSUs) vesting on the first, second, and third anniversary of the grant date in equal amounts (i.e 1/3 of the options and RSUs will vest on each anniversary of the grant date, being June 6 of each relevant year) o 14,820 tenure-based options and RSUs ( 4,446 options and 10,374 RSUs) granted to Cary Vance and Robert McNamara as an initial grant in connection with their appointment to the Board of Directors. Employee Stock Purchase Plan In June 2023, the stockholders approved the AVITA Medical, Inc. Employee Stock Purchase Plan (the “ ESPP ”). The ESPP became effective on July 1, 2023 . On June 30, 2023, the Company filed Registration Statement on Form S-8 to register 1,000,000 shares of common stock under the ESPP, as a result of the Company’s stockholders approving the ESPP at the 2023 Annual Meeting. The ESPP is implemented by a series of offering periods, each of which is six months in duration, with new offering periods commencing on the first trading date of June and December of each year. The first offering period for the ESPP is July 3 – November 30, 2023. Subsequent offering periods will be the first trading day of November to the last trading day of May and the first trading date of June to the last trading day of December. The ESPP provides eligible employees with an opportunity to purchase shares of the Company’s common stock through payroll deductions of up to 15 % of their eligible compensation. A participant may purchase a maximum of 5,000 shares of common stock during an offering period. Amounts deducted and accumulated by the participant are used to purchase shares of common stock at the end of each six-month purchase period. The purchase price of the shares is 85 % of the lower of the fair market value of the common stock on (i) the first trading day of the applicable offering period and (ii) the last trading day of each purchase period in the related offering period. Participants may withdraw from the offering at least 21 days before the purchase date. Accrued contributions that have not yet been used to purchase shares of common stock will be repaid to the participant. Termination of employment at least 30 days prior to the purchase date results in withdrawal from the offering and contributions are returned to the participant. If termination of employment occurs within 30 days of the purchase date, contributions are used to purchase shares on the purchase date. Employee payroll contributions ultimately used to purchase shares are reclassified to stockholders’ equity on the purchase date. As of June 30, 2023 and December 31, 2022, the Company does not have any accrued payroll contributions.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes Tax expense for the three-months ended June 30, 2023 and 2022 was $ 13,000 and $ 4,000 , respectively, and $ 43,000 and $ 8,000 for the six-months ended June 30, 2023 and 2022, respectively. These amounts are related to state minimum taxes.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	16. Net Loss per Share The following is a reconciliation of the basic and diluted loss per share computations: Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 (in thousands, except per share amounts) Net Loss $ 10,384 $ 6,261 $ 19,604 $ 15,724 Weighted-average common shares—outstanding, basic and diluted 25,240 24,971 25,221 24,955 Net loss per common share, basic and diluted $ 0.41 $ 0.25 $ 0.78 $ 0.63 Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Anti-dilutive shares excluded from diluted net loss per common share: Stock options 2,675,458 1,774,070 2,675,458 1,774,070 Restricted stock units 378,541 220,920 378,541 220,920 The Company’s basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the relevant period. In accordance with ASC 710-10 , 105,577 shares of common stock held by the rabbi trust are excluded from the denominator in the basic and diluted net loss per common share calculations. For details on shares of common stock held by the rabbi trust refer to Note 17. For the purposes of the calculation of diluted net loss per share, options to purchase common stock, restricted stock units and unvested shares of common stock issued upon the early exercise of stock options have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Because the Company has reported a net loss for the three-months and six-months ended June 30, 2023, and 2022, diluted net loss per common share is the same as the basic net loss per share for those periods.

Retirement Plans

Retirement Plans	6 Months Ended
	Jun. 30, 2023
Compensation And Retirement Disclosure [Abstract]
Retirement Plans	17. Retirement Plans The Company offers a 401(k) retirement savings plan (the “401(k) Plan” ) for its employees, including its executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code of 1986, as amended, allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) Plan. The Company matches contributions to the 401(k) Plan based on the amount of salary deferral contributions the participant makes to the 401(k) Plan. The Company will match up to 6 % of an employee’s compensation that the employee contributes to his or her 401(k) Plan account up to the maximum allowable. Total Company's matching contributions to the 401(k) Plan were $ 249,000 and $ 239,000 for the three-months ended June 30, 2023 and 2022, respectively, and $ 671,000 and $ 471,000 for the six-months ended June 30, 2023 and 2022, respectively. Non-Qualified Deferred Compensation Plan The Company’s NQDC plan, which became effective on October 2021, allows for eligible management and highly compensated key employees to elect to defer a portion of their salary, bonus and RSU awards to later years. Cash deferrals are immediately vested and are subject to investment risk, and a risk of forfeiture under certain circumstances. RSU deferrals are subject to the vesting conditions of the award. Once RSUs vest, subject to a six-month and one day holding period, employees are allowed to diversify the common stock into other investment options offered by the plan. For cash deferrals, the Company matches 4 % to 6 % (depending on level) of employee contributions. These matching employer contributions are vested over a two-year period with 25 % vesting on year one and 75 % vesting on year two for employees under 55 years of age. Employer contributions for employees over 55 years of age are immediately vested. Employer contributions to the NQDC plan were $ 39,000 and $ 38,000 for the three-months ended June 30, 2023 and 2022, respectively, and $ 80,000 and $ 122,000 for the six-months ended June 30, 2023 and 2022, respectively. The Company’s deferred compensation plan liability was $ 3.8 million and $ 1.3 million as of June 30, 2023 and December 31, 2022, respectively. These amounts are split between current and long term on the Consolidated Balance Sheets. As of June 30, 2023, $ 2.6 million is included in Current non-qualified deferred compensation liability and $ 1.2 million in Non-qualified deferred compensation liability. As of December 31, 2022, $ 78,000 is included in Current non-qualified deferred compensation liability and $ 1.3 million in Non-qualified deferred compensation liability. During the second quarter of 2023, the Company had a payout of approximately $ 82,000 in the deferred compensation liability for a terminated employee. The fair values of the Company’s deferred compensation plan assets and liability are included in the table below. For additional information on the fair value hierarchy and the inputs used to measure fair value, see Note 4, Fair Value Measurements. Fair Value as of June 30, 2023 Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Corporate-owned life insurance policies (1) $ - $ 2,091 $ - $ 2,091 $ - $ 1,238 $ - $ 1,238 Non-qualified deferred compensation plan liability (2) - 3,796 - 3,796 - 1,348 - 1,348 (1) The corporate-owned life insurance contracts are recorded at cash surrender value, which is provided by a third party and reflects the net asset value of the underlying publicly traded mutual funds and are categorized as Level 2. (2) Non-qualified deferred compensation plan liability is measured at fair value based on quoted prices of identical instruments to the investment vehicles selected by the participants. Rabbi Trust During April 2022, the Company established a rabbi trust to hold the assets of the NQDC plan. The rabbi trust holds the COLI asset and the common stock from deferred RSU awards that have vested. The NQDC permits diversification of fully vested shares into other equity securities subject to a six-month and one day holding period. In accordance with ASR 268, Redeemable Preferred Stock , and ASC 718, Compensation — Stock Compensation , prior to vesting, the deferred share awards are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. The redemption amounts of the deferred awards are based on the vested percentage and are recorded outside of permanent equity as Non-qualified deferred compensation share awards on the Consolidated Balance Sheets. As of June 30, 2023, a total of 165,399 shares awards have been deferred, and a total of 105,577 shares were vested at the redemption value of $ 892,000 . As of December 31, 2022, a total of 253,048 share awards have been deferred, and a total of 17,927 awards vested with a redemption value of $ 127,000 . Vested shares are converted to common stock and are reclassified to permanent equity. Common stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Common stock held by the NQDC plan. The following table summarizes the eligible share award activity as of June 30, 2023 and December 31, 2022 (in thousands): As of (in thousands) June 30, 2023 December 31, 2022 Non-qualified deferred compensation share awards: Balance at inception/beginning of period $ 557 $ - Change in classification of deferred compensation share awards - 192 Stock-based compensation expense 411 471 Change in redemption value 1,025 21 Vesting of share awards held by NDQC ( 765 ) ( 127 ) Ending Balance $ 1,228 $ 557

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no events that have occurred that would require adjustments to our disclosures in the Consolidated Financial Statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP ”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “ SEC ”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2022 filed with the SEC on February 23, 2023 and the Australian Securities Exchange (" ASX ") on February 24, 2023 (the “Annual Report" ). There have been no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K that have had a material impact on the Company’s Consolidated Financial Statements. See the summary of the Company’s significant accounting policies set forth in the notes to its Consolidated Financial Statements included in the Annual Report.
Principles of Consolidation	Principles of Consolidation The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.
Reclassification of prior year presentation	Reclassification of prior year presentation Certain prior year amounts within Other current liabilities have been reclassified to Current non-qualified deferred compensation liability, in the Consolidated Balance Sheets for consistency with current period presentation. These reclassifications had no effect on the reported results of operations or financial position.
Recent Accounting Pronouncements	Recent Accounting Pronouncements No new accounting standards were adopted during the three-months and six-months ended June 30, 2023. The Company considers the applicability and impact of recent Accounting Standard Updates (" ASUs ") issued by the Financial Accounting Standards Board (" FASB "). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company's Consolidated Financial Statements.
Use of Estimates	Use of Estimates The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, stock-based compensation, and the stand-alone selling price for the Biomedical Advanced Research and Development Authority ( "BARDA" ) contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in Other comprehensive gain (loss) in Stockholders’ Equity. Gains and losses resulting from foreign currency transactions are included in General and administrative expenses in the Consolidated Statement of Operations. Amounts for the three-months ended June 30, 2023 were insignificant, and for the three-months ended June 30, 2022, the Company had a gain of $ 69,000 . Gains and losses resulting from foreign currency transactions were a gain of $ 11,000 and gain of $ 47,000 for the six-months ended June 30, 2023 and 2022, respectively. The Company’s non-operating subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements, and foreign currency transactions are included in General and administrative expenses in the Consolidated Statement of Operations. During the three-months ended June 30, 2023 and 2022, the Company recorded a loss of $ 6,000 and a gain of $ 7,000 , respectively. During the six-months ended June 30, 2023 and 2022, the Company recorded a loss of $ 15,000 and a loss of $ 8,000 , respectively
Comprehensive Loss	Comprehensive Loss The components of comprehensive loss consist of net loss, foreign currency translation adjustments from the Company's subsidiaries not using the U.S. dollar as their functional currency and unrealized gains and losses in investments available-for-sale. The Company did not have reclassifications from other comprehensive loss to net loss during the three-months and six-months ended June 30, 2023 and 2022.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standard Codification (“ ASC ”) Topic 606 , Revenue Recognition , the Company performs the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations 5. Recognize revenue when/as performance obligation(s) are satisfied In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. Once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised with each contract, determines whether those are performance obligations and the related transaction price. The Company then recognizes the sale of goods based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company’s revenue consists primarily of the sale of the RECELL System to hospitals, treatment centers, COSMOTEC and to BARDA (collectively, “ customers ”), predominately in the United States. The Company evaluated the BARDA contract and concluded that a portion of the arrangement, such as the procurement of the RECELL system and the emergency preparedness, represents a transaction with a customer and as such are in the scope of ASC 606 . Amounts received from BARDA for the research and development of the Company’s product are classified as BARDA income in the Consolidated Statements of Operations and are accounted for under IAS 20 by analogy. For further details refer to BARDA Income and Receivables below. Revenues for commercial customers (hospitals, treatment centers and COSMOTEC) are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. For the Company’s contracts that have an original duration of one year or less, the Company elected the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfillment costs such as commissions and shipping and handling expenses as incurred. For revenues related to the BARDA contract within the scope of ASC 606 , the Company identified two performance obligations: (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services. Under this contract the Company promises to procure the product through a vendor management inventory arrangement and to stand ready to provide emergency deployment services related to the product. Emergency preparedness services include procuring necessary storage containers, housing, and maintaining the containers (and product), and providing shipping and handling services in the event of an emergency situation. This stand ready obligation is a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, over time as services are consumed. The total transaction price for the portion of the BARDA contract that is within the scope of ASC 606 was determined to be $ 9.2 million. The transaction price was allocated on a stand-alone selling price basis as follows: $ 7.6 million to the procurement of the RECELL product, which is classified as Revenues when recognized in the Consolidated Statements of Operations and $ 1.6 million to the emergency deployment services which is classified as Revenues when recognized in the Consolidated Statements of Operations. The $ 1.6 million for emergency deployment includes variable consideration which is deemed immaterial to the contract as a whole. The Company estimated the stand-alone selling price of the procurement of the RECELL product based on historical pricing of the Company’s product at the initial execution of the contract. The Company estimated the stand-alone selling price of the emergency deployment services performed based on the Company’s projected cost of providing the services plus an applicable profit margin as denoted in the contract. The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. The product procurement performance obligation is satisfied at a point in time, upon transfer of control of the product. As such, the related revenue for these performance obligations is recognized at a point in time as Revenue within the Company’s Consolidated Statement of Operations. In addition to guidance under ASC 606 , the Company recognizes revenue from the sales of RECELL product to BARDA for placement into vaccine stockpiles in accordance with SEC Interpretation , Commission Guidance regarding Accounting for Sale of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS). Under this guidance, revenue is recognized when product is placed in the BARDA vendor-managed inventory (" VMI ") as control of the product has been transferred to the customer at the time of delivery to the VMI. RECELL units that have been delivered to BARDA have a product replacement obligation at no cost to BARDA due to the product’s limited shelf-life. The estimated cost of the expired inventory over the term of the contract is recognized on a per unit basis at the time of delivery. The liability is released upon replacement of the product along with a corresponding reduction to inventory. The emergency preparedness services performance obligation is satisfied over time. Revenue for the emergency deployment will be recognized on a straight-line basis during the term of the contract as services are consumed over time. Services recognized are included in Revenues within the Consolidated Statements of Operations. Contract costs to fulfill the performance obligations are incremental and expected to be recovered are capitalized and amortized on a straight-line basis over the term of the contract. Contract costs are included in Prepaids and other current assets in the Consolidated Balance Sheets. For further details refer to Note 5.
Contract Liabilities	Contract Liabilities The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30 - 90 days , and do not include a financing component. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. For further details refer to Note 5.
Cost of Sales	Cost of Sales Cost of sales related to products includes costs to manufacture or purchase, package, and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash held at deposit institutions and cash equivalents. Cash equivalents consist of short-term highly liquid investments with original maturities of three months or less from the date of purchase and consist primarily of money market funds. The Company holds cash at deposit institutions in the amount of $ 5.8 million and $ 4.1 million, of which $ 697,000 and $ 737,000 is denominated in foreign currencies in foreign institutions as of June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company held cash equivalents in the amount of $ 31.7 million and $ 14.1 million, respectively.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, BARDA receivables and other receivables. As of June 30, 2023 and December 31, 2022, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits and subject to the risk of bank failure. As of June 30, 2023 no single commercial customer accounted for more than 10 % of net accounts receivable. As of December 31, 2022, one commercial customer accounted for more than 10 % of total net accounts receivable. For the three-months and six-months ended June 30, 2023 and 2022, no single customer accounted for more than 10 % of revenues. BARDA revenue for emergency deployment accounted for less than 1 % of total revenues for the three-months and six-months ended June 30, 2023 and 2022. BARDA receivables for emergency preparedness services accounted for 4 % and 2 % of total BARDA receivables as of June 30, 2023 and December 31, 2022, respectively. See table below for breakdown of BARDA receivables (in thousands). As of June 30, 2023 December 31, 2022 BARDA procurement and emergency preparedness services $ 16 $ 16 BARDA expense reimbursements 426 882 Total $ 442 $ 898
Marketable Securities	Marketable Securities We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date . Classification is determined at the time of purchase and re-evaluated each balance sheet date. Short-term marketable securities represent investment of cash available for current operations. All marketable securities, which consist of corporate debt securities, asset backed securities, U.S government agency obligations, U.S treasury and commercial paper are denominated in U.S. dollars, have been classified as “available-for-sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in Other comprehensive income (loss) and reported as a separate component of Stockholders' Equity until realized. Realized gains and losses on marketable securities are included in Other income in the accompanying Consolidated Statements of Operations. The cost of any marketable securities sold is based on the specific identification method. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in Other income in the accompanying Consolidated Statements of Operations. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the maximum final maturity from the date of purchase is thirty-seven months . If necessary, the Company will recognize an allowance for credit losses on available-for-sale debt securities on an individual basis and will no longer consider other-than-temporary impairment or immediately reduce the cost basis of the investment, provided that it is more likely than not that the security will be held to recovery or maturity. Further, the Company will recognize any improvements in estimated credit losses on available-for-sale debt securities immediately in earnings and reduce the existing allowance for credit losses. The Company will disaggregate its available-for-sale debt securities into the following categories: commercial paper, corporate debt, government and agency securities, asset backed securities and money market funds. The Company’s corporate bonds are comprised of predominantly high-grade corporate bonds while its government and agency securities are U.S. treasury bonds, and U.S. agency bonds. The Company has analyzed both corporate bonds and government and agency securities and identified that both types of securities have similar risk characteristics in that they are traded infrequently and have contractual interest rates and maturity dates. To evaluate for impairment, management reviews credit rating changes, securities trends, interest rate movements and unrealized loss at the security level of the Company’s available-for-sale debt securities. If any of these give rise to a potential credit concern, the Company performs a discounted cash flow analysis to determine the credit portion of the impairment. The discounted cash flow analysis will be performed either internally or through the assistance of a qualified third party. Once the credit component of the impairment is determined, the Company will record the impaired amount as an allowance to the available-for-sale debt securities balance and as a charge to Other income in the accompanying Consolidated Statements of Operations, not to exceed the amount of the unrealized loss. The Company assesses expected credit losses at the end of each reporting period and adjusts the allowance through Other income.
BARDA Income and Receivables	BARDA Income and Receivables The Company was awarded the BARDA grant in September 2015. Under this grant, BARDA supported the Company’s research and development for the Company’s product, including the U.S. clinical regulatory program targeted towards FDA PMA, compassionate use programs, clinical and health economics research, and U.S. pediatric burn programs. Currently, the BARDA contract is supporting the Company's clinical trial in soft-tissue reconstruction, which led to the full-thickness skin defect indication. Consideration received under the BARDA grant is earned and recognized under a cost-plus-fixed-fee arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs and a fixed-fee earned. Billings under the contracts are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, general and administrative expenses and a fixed fee. The Company has concluded that grants under the BARDA grant are not within the scope of ASC 606 , as they do not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition also does not apply, as the Company is a business entity, and the grants are with governmental agencies or units. With respect to the BARDA grant, we considered the guidance in IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy. BARDA income and related receivables are recognized when there is reasonable assurance that the grant will be received, and all attaching conditions have been complied with. When the grant relates to an expense item, the grant received is recognized as income over the period when the expense was incurred.
Leases	Leases The Company has operating leases for c orporate office space, manufacturing and a warehouse facility. The Company’s operating leases have remaining lease terms of one year to three years , so me of which include options to renew the lease. At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the Consolidated Balance Sheets. Right-of-use (“ ROU ”) assets represent the Company’s right to control an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an explicit rate, the Company used its incremental borrowing rate (“ IBR ”) based on the information available at the commencement date in determining the discount rate used to present value lease payments. In determining the IBR, the Company considered its credit rating and current market interest rates. The IBR used approximates the interest that the Company would be required to pay for a collateralized loan over a similar term. The Company’s leases typically do not include any residual value guarantees or asset retirement obligations. The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. Lease expense is recognized on a straight-line basis over the lease term and is primarily included in General and administrative expenses in the accompanying Consolidated Statements of Operations. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all underlying asset classes. Some leases require variable payments for common area maintenance, property taxes, parking, insurance and other variable costs. The variable portion of lease payments is not included in operating lease assets or liabilities. Variable lease costs are expensed when incurred.
Stock-Based Compensation	Stock-Based Compensation The Company records compensation expense for stock options and restricted stock units (" RSU ") based on the fair market value of the awards on the date of grant. The fair value of stock-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is evaluated based on the number of shares ultimately expected to vest, evaluated each reporting period and based on management’s expectations regarding the relevant performance criteria. The Black-Scholes option pricing model and Monte Carlo Simulation are used to estimate the fair value of the time-based and performance-based options, respectively. Under ASU 2016-09 , Compensation – Stock Compensation (“ASC 718”) Improvements to Employee Share-Based Payment Accounting , the Company elected to account for forfeitures as they occur. The following assumptions were used in the valuation of stock options. • Expected volatility – determined using the average of the historical volatility using daily intervals over the expected term and the derived volatility using the longest term available of 12 months. • Expected dividends - based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future • Expected term – the expected term of the Company’s stock options for tenure only vesting has been determined utilizing the “simplified” method as described in the SEC’s Staff Accounting Bulletin No. 107 relating to share-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history of awards granted, with the first plan being established in 2016 which was primarily used for executive awards. Further, the Company does not have sufficient history of exercises in the U.S. market given the Company’s redomiciliation from Australia to the United States in 2020. The expected term of options with a performance condition or market condition was set to the contractual term of 10 years. The contractual term was used for options with a performance or market condition as these are primarily awarded to executives and the Company assumes that they will hold them longer than rank and file employees. • Risk-free interest rate – the risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award.
Non-Qualified Deferred Compensation Plan Liability and Corporate-Owned Life Insurance Asset	Non-Qualified Deferred Compensation Plan Liability and Corporate-Owned Life Insurance Asset The Company’s non-qualified deferred compensation plan (the " NQDC plan "), which became effective in October 2021, allows highly compensated key employees to elect to defer a portion of their salary, bonus and RSU awards to later years. Management determined that the cash deferrals under the NQDC plan shall be accounted for similarly to a defined benefit plan under ASC 715 , Compensation – Retirement Benefits , and should follow accounting treatment that is similar to a cash balance plan. Management determined that the employee portion and employer portion of the deferred compensation should be recognized as a compensation expense with a corresponding credit to deferred compensation liability. The matching contribution will be accrued over the vesting period of two years with 25 % vesting in the first year and 75 % vesting in the second year. Employees aged 55 or older immediately vest in employer matching contributions. The change in the liability between each reporting period is accounted for as compensation expense with a corresponding adjustment to deferred compensation liability. Upon distribution, the Company will record the distribution as a decrease to deferred compensation liability with a corresponding credit to cash. The Company funds the NQDC plan through a Corporate-Owned Life Insurance ( “COLI” ). Per the ASC 325-30-25-1A, Investments – Other , COLI is recorded as an asset on the Consolidated Balance Sheets as it does not meet the definition of a plan asset under ASC 715 . The Company invests in COLI policies relating to its deferred compensation plan. Investments in COLI policies are recorded at their cash surrender values as of each balance sheet date. Changes in the cash surrender value during the period are recorded as a gain or loss in the Consolidated Statements of Operations in Other income.
Rabbi Trust	Rabbi Trust During April 2022, the Company established a rabbi trust for a select group of participants in which share awards granted under the 2020 Omnibus Incentive Plan ( “2020 Plan” ) and deferred under the NQDC plan may be deposited. In addition to the deferral of shares, the rabbi trust holds the assets in the COLI for the NQDC plan. The rabbi trust is an irrevocable trust, and no portion of the trust fund may be used for any purpose other than the delivery of those assets to the participants. The assets held in the rabbi trust are subject to the claims of our general creditors in the event of bankruptcy or insolvency. The value of the assets of the rabbi trust is consolidated into our financial statements. The NQDC plan permits diversification of vested shares (common stock) into other equity securities subject to a six-month and one day holding period subsequent to vesting. Per ASC 710-10-25-15 , accounting for deferred common stock will be under plan type C or D. Accounting will depend on whether or not the employee has diversified the common stock. Under Plan type C, diversification is permitted but the employee has not diversified. Under plan type D, diversification is permitted, and the employee has diversified. For common stock that have not been diversified, the employer stock held in the rabbi trust is classified in a manner similar to treasury stock and presented separately on the Consolidated Balance Sheets as Company common stock held by the NQDC plan. The common stock will be recorded at the fair value of the stock at the time it vested, subsequent changes in the value of the common stock will not be recognized. The deferred compensation obligation is measured independently at fair value of the common stock with a corresponding charge or credit to compensation cost. The fair value is calculated as the product of the common stock and the closing price of the stock each reporting period. Under plan type D, the accounting for the assets held by the rabbi trust is subject to the accounting pronouncements under applicable GAAP for each asset type. As diversified common stock will be invested in mutual funds, assets held by the rabbi trust will be subject to accounting under ASC 321 - Investments - Equity Securities . The deferred compensation obligation is measured independently at fair value of the underlying assets. As of June 30, 2023, none of the deferred common stock has been diversified.
Non-Qualified Deferred Compensation Stock Awards	Non-Qualified Deferred Compensation Stock Awards In accordance with ASC 718, Compensation — Stock Compensation , the deferred RSU awards under the NQDC plan are classified as an equity instrument and changes in fair value of the amount owed to the participant are not recognized. As the plan permits diversification, presentation outside of permanent equity in accordance with ASR 268, Redeemable Preferred Stock is appropriate. The redemption amounts are based on the vested percentage and are recorded outside of equity as Non-qualified deferred compensation share awards on the Consolidated Balance Sheets. Deferred awards will be presented outside of permanent equity until the awards are vested. For further details refer to Note 17.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Other Receivables	See table below for breakdown of BARDA receivables (in thousands). As of June 30, 2023 December 31, 2022 BARDA procurement and emergency preparedness services $ 16 $ 16 BARDA expense reimbursements 426 882 Total $ 442 $ 898

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2023
Available For Sale Securities [Abstract]
Summary of Amortized Cost and Estimated Fair Values of Debt Securities Available for Sale	The following table summarizes the amortized cost and estimated fair values of debt securities available-for-sale: As of June 30, 2023 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 30,669 $ - $ - $ 30,669 U.S. Treasury securities 999 1 - 1,000 Total cash equivalents $ 31,668 $ 1 $ - $ 31,669 Current marketable securities: U.S. Treasury securities $ 23,227 $ - $ ( 69 ) $ 23,158 Commercial paper 2,311 - - 2,311 Corporate debt securities 1,422 - ( 5 ) 1,417 U.S. Government agency obligations 1,681 - ( 5 ) 1,676 Total current marketable securities $ 28,641 $ - $ ( 79 ) $ 28,562 Long-term marketable securities: Asset backed securities $ 2,759 $ 2 $ ( 7 ) $ 2,754 Total long-term marketable securities $ 2,759 $ 2 $ ( 7 ) $ 2,754 As of December 31, 2022 Amortized Gross Gross Carrying (in thousands) Cash equivalents: Money market funds $ 14,089 $ - $ - $ 14,089 Current marketable securities: U.S. Treasury securities $ 43,092 $ 1 $ ( 393 ) $ 42,700 Commercial paper 12,743 - - 12,743 Corporate debt securities 3,865 - ( 23 ) 3,842 U.S. Government agency obligations 1,901 - ( 8 ) 1,893 Total current marketable securities $ 61,601 $ 1 $ ( 424 ) $ 61,178 Long-term marketable securities: Asset backed securities $ 3,568 $ 7 $ ( 3 ) $ 3,572 U.S. Treasury securities 2,416 - ( 6 ) 2,410 U.S. Government agency obligations 949 - ( 1 ) 948 Total long-term marketable securities $ 6,933 $ 7 $ ( 10 ) $ 6,930
Summary of Maturities of Debt Securities Available for Sale	The maturities of debt securities available-for-sale are summarized in the following table using contractual maturities. Actual maturities may differ from contractual maturities due to obligations that are called or prepaid. As of June 30, 2023 As of December 31, 2022 (in thousands) Amortized Carrying Amortized Carrying Due in one year or less $ 28,641 $ 28,562 $ 61,601 $ 61,178 Due after one year through three years $ 2,759 $ 2,754 $ 6,933 $ 6,930

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Financial Assets Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: As of June 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 30,669 $ - $ - $ 30,669 U.S. Treasury securities - 1,000 - 1,000 Total Cash equivalents $ 30,669 $ 1,000 $ - $ 31,669 Current marketable securities: U.S. Treasury securities $ - $ 23,158 $ - $ 23,158 Commercial paper - 2,311 - 2,311 Corporate debt securities - 1,417 - 1,417 U.S. Government agency obligations - 1,676 - 1,676 Total current marketable securities $ - $ 28,562 $ - $ 28,562 Long-term marketable securities: Asset backed securities $ - $ 2,754 $ - $ 2,754 Total long-term marketable securities $ - $ 2,754 $ - $ 2,754 Total marketable securities and cash equivalents $ 30,669 $ 32,316 $ - $ 62,985 As of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 14,089 $ - $ - $ 14,089 Current marketable securities: U.S. Treasury securities - 42,700 - 42,700 Commercial paper - 12,743 - 12,743 Corporate debt securities - 3,842 - 3,842 U.S. Government agency obligations - 1,893 - 1,893 Total current marketable securities $ - $ 61,178 $ - $ 61,178 Long-term marketable securities: Asset backed securities $ - $ 3,572 $ - $ 3,572 U.S. Treasury securities - 2,410 - 2,410 U.S. Government agency obligations - 948 - 948 Total long-term marketable securities $ - $ 6,930 $ - $ 6,930 Total marketable securities and cash equivalents $ 14,089 $ 68,108 $ - $ 82,197

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Summary Of Lease Cost	The following table sets forth the Company’s operating lease expenses which are included in General and administrative expenses in the Consolidated Statements of Operations (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Operating lease cost $ 197 $ 194 $ 395 $ 388 Variable lease cost 13 13 26 25 Total lease cost $ 210 $ 207 $ 421 $ 413
Summary Of Supplemental Cash Flow Information Related To Operating Leases	Supplemental cash flow information related to Operating leases for the three-months and six-months ended June 30, 2023 and 2022 was as follows (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 205 $ 199 $ 410 $ 397
Summary Of Supplemental Balance Sheet Information Related To Operating Leases	Supplemental balance sheet information, as of June 30, 2023 and December 31, 2022, related to operating leases was as follows (in thousands, except for Operating lease weighted average remaining lease term and operating lease weighted average discount rate): As of June 30, 2023 December 31, 2022 Reported as: Operating lease right-of-use assets $ 1,651 $ 851 Total right-of-use assets $ 1,651 $ 851 Other current liabilities : Operating lease liabilities, short-term $ 656 $ 612 Operating lease liabilities, long term 1,047 306 Total operating lease liabilities $ 1,703 $ 918 Operating lease weighted average remaining lease term (years) 2.73 1.44 Operating lease weighted average discount rate 7.93 % 6.71 %
Summary Of Maturities Of The Company's Operating Lease Liabilities	As of June 30, 2023, maturities of the Company’s operating lease liabilities are as follows (in thousands): Operating Leases Remainder of 2023 $ 345 2024 741 2025 441 2026 377 Total lease payments 1,904 Less imputed interest ( 201 ) Total operating lease liabilities $ 1,703

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Summary Of Composition Of Inventory	The composition of inventory is as follows (in thousands): As of June 30, 2023 December 31, 2022 Raw materials $ 1,882 $ 1,131 Work in process 491 384 Finished goods 685 610 Total inventory $ 3,058 $ 2,125

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill And Intangible Assets Disclosure [Abstract]
Summary Of Composition Of Intangible Assets	The composition of intangible assets, net is as follows (in thousands): As of June 30, 2023 As of December 31, 2022 Weighted Gross Accumulated Net Gross Accumulated Net Patent 1 3 $ 17 $ ( 16 ) $ 1 $ 17 $ ( 16 ) $ 1 Patent 2 13 138 ( 33 ) 105 137 ( 28 ) 109 Patent 3 14 195 ( 46 ) 149 194 ( 39 ) 155 Patent 5 19 98 ( 9 ) 89 89 ( 6 ) 83 Patent 6 20 44 ( 5 ) 39 43 ( 4 ) 39 Patent 7 13 2 - 2 2 - 2 Patent 8 19 10 ( 1 ) 9 13 - 13 Patent 10 19 3 - 3 3 - 3 Patent 11 19 6 ( 1 ) 5 6 - 6 Trademarks Indefinite 54 - 54 54 - 54 Total intangible assets $ 567 $ ( 111 ) $ 456 $ 558 $ ( 93 ) $ 465
Summary Of Future Amortization Of Amortizable Intangible Assets Held	The Company expects the future amortization of amortizable intangible assets held at June 30, 2023 to be as follows (in thousands): Estimated Remainder of 2023 $ 17 2024 34 2025 34 2026 34 2027 33 2028 33 Thereafter 217 Total $ 402

Plant and Equipment (Tables)

Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property Plant And Equipment [Abstract]
Summary of Composition of Property, Plant and Equipment	The composition of property, plant and equipment, net is as follows (in thousands): As of Useful Lives June 30, 2023 December 31, 2022 Computer equipment 3 years $ 889 $ 755 Computer software 3 years 980 871 Construction in progress 423 258 Furniture and fixtures 7 years 616 439 Laboratory equipment 5 years 696 643 Leasehold improvements Lesser of life or lease term 257 257 RECELL moulds 5 years 128 129 Less: accumulated amortization and depreciation ( 2,391 ) ( 2,152 ) Total plant and equipment, net $ 1,598 $ 1,200

Other Current and Long-Term A_2

Other Current and Long-Term Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Other Current And Long Term Assets And Liabilities [Abstract]
Summary of Prepaids and Other Current Assets	Prepaids and other current assets consisted of the following (in thousands): As of June 30, 2023 December 31, 2022 Prepaid expenses $ 1,375 $ 921 Lease deposits - 110 Accrued investment income 168 168 BARDA contract costs 126 252 Other receivables 525 127 Total prepaids and other current assets $ 2,194 $ 1,578
Summary of Other Long Term Assets	Other long-term assets consisted of the following (in thousands): As of June 30, 2023 December 31, 2022 Long-term lease deposits $ 189 $ 25 Long-term prepaids 96 97 Total other long-term assets $ 285 $ 122
Summary of Other Current Liabilities	Other current liabilities consisted of the following (in thousands): As of June 30, 2023 December 31, 2022 Operating lease liability $ 656 $ 612 BARDA deferred costs 130 194 BARDA deferred revenue 183 - Other current liabilities 232 184 Total other current liabilities $ 1,201 $ 990

Reporting Segment and Geograp_2

Reporting Segment and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule Of Revenue and Cost Of Sales By Region and Customer Type	Revenue by region for the three-months and six-months ended June 30, 2023 and 2022 were as follows (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Revenue: United States $ 10,992 $ 8,278 $ 20,417 $ 15,676 Foreign: Japan 708 - 1,729 - Australia 33 29 95 116 United Kingdom 20 28 62 82 Total $ 11,753 $ 8,335 $ 22,303 $ 15,874 Revenue and cost of sales by customer type for the three-months and six-months ended June 30, 2023 and 2022 were as follows (in thousands): Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Revenue: Commercial sales $ 11,686 $ 8,242 $ 22,143 $ 15,688 BARDA: Services for emergency preparedness 67 93 160 186 Total $ 11,753 $ 8,335 $ 22,303 $ 15,874 Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Cost of sales: Commercial cost $ 2,108 $ 1,302 $ 3,724 $ 3,007 BARDA: Product cost 11 - ( 23 ) ( 12 ) Emergency preparedness service cost 85 84 170 169 Total $ 2,204 $ 1,386 $ 3,871 $ 3,164

Stock-Based Payment Plans (Tabl

Stock-Based Payment Plans (Tables)	6 Months Ended
	Jun. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary Of Stock-based Compensation Is Reflected In The Statements Of Operations	The Company has included stock-based compensation expense as part of operating expenses in the accompanying Consolidated Statements of Operations as follows: Three-Months Ended Six-Months Ended (In thousands) June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Sales and marketing expenses $ 76 $ 285 $ 401 $ 614 General and administrative expenses 818 983 2,908 3,310 Research and development expenses 249 146 474 422 Total $ 1,143 $ 1,414 $ 3,783 $ 4,346
Summary Of Share Option Activity	A summary of share option activity as of June 30, 2023, and changes during the period ended is presented below: Service Only Share Options Performance Based Share Options Total Share Options Outstanding shares at December 31, 2022 1,724,252 511,194 2,235,446 Granted 889,193 - 889,193 Exercised ( 116,529 ) ( 30,000 ) ( 146,529 ) Expired ( 59,125 ) ( 178,156 ) ( 237,281 ) Forfeited ( 58,413 ) ( 6,958 ) ( 65,371 ) Outstanding shares at June 30, 2023 2,379,378 296,080 2,675,458 Exercisable at June 30, 2023 720,303 235,896 956,199
Non Option Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary Of Share Option Activity	A summary of the status of the Company’s unvested RSUs as of June 30, 2023, and changes that occurred during the period is presented below: Unvested Shares Tenure-Based RSUs Performance Total RSUs Unvested RSUs outstanding at December 31, 2022 394,872 65,646 460,518 Granted 57,798 - 57,798 Vested ( 76,900 ) ( 15,750 ) ( 92,650 ) Forfeited ( 39,250 ) ( 7,875 ) ( 47,125 ) Unvested RSUs outstanding at June 30, 2023 336,520 42,021 378,541

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Summary Of Reconciliation Of The Basic And Diluted Loss Per Share	The following is a reconciliation of the basic and diluted loss per share computations: Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 (in thousands, except per share amounts) Net Loss $ 10,384 $ 6,261 $ 19,604 $ 15,724 Weighted-average common shares—outstanding, basic and diluted 25,240 24,971 25,221 24,955 Net loss per common share, basic and diluted $ 0.41 $ 0.25 $ 0.78 $ 0.63 Three-Months Ended Six-Months Ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Anti-dilutive shares excluded from diluted net loss per common share: Stock options 2,675,458 1,774,070 2,675,458 1,774,070 Restricted stock units 378,541 220,920 378,541 220,920

Retirement Plans (Tables)

Retirement Plans (Tables)	6 Months Ended
	Jun. 30, 2023
Compensation And Retirement Disclosure [Abstract]
Summary of Fair Values of Company's Deferred Compensation Plan Assets and Liability	The fair values of the Company’s deferred compensation plan assets and liability are included in the table below. For additional information on the fair value hierarchy and the inputs used to measure fair value, see Note 4, Fair Value Measurements. Fair Value as of June 30, 2023 Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Corporate-owned life insurance policies (1) $ - $ 2,091 $ - $ 2,091 $ - $ 1,238 $ - $ 1,238 Non-qualified deferred compensation plan liability (2) - 3,796 - 3,796 - 1,348 - 1,348 (1) The corporate-owned life insurance contracts are recorded at cash surrender value, which is provided by a third party and reflects the net asset value of the underlying publicly traded mutual funds and are categorized as Level 2. (2) Non-qualified deferred compensation plan liability is measured at fair value based on quoted prices of identical instruments to the investment vehicles selected by the participants.
Summary of Eligible Share Award Activity	The following table summarizes the eligible share award activity as of June 30, 2023 and December 31, 2022 (in thousands): As of (in thousands) June 30, 2023 December 31, 2022 Non-qualified deferred compensation share awards: Balance at inception/beginning of period $ 557 $ - Change in classification of deferred compensation share awards - 192 Stock-based compensation expense 411 471 Change in redemption value 1,025 21 Vesting of share awards held by NDQC ( 765 ) ( 127 ) Ending Balance $ 1,228 $ 557

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Segment PerformanceObligation shares	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) shares
Summary Of Significant Accounting Policies [Line Items]
Gain (loss) on foreign currency transactions			$ (4,000)	$ 39,000
Contract description			For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations: (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services.
Cash at deposit institutions	$ 5,800,000		$ 5,800,000		$ 4,100,000
Cash in foreign institutions	697,000		697,000		737,000
Cash equivalents held	$ 31,700,000		$ 31,700,000		$ 14,100,000
Description of maturity terms			We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date
Final maturity period			37 months
Lease renewal period	3 years		3 years
Contractual term			10 years
Number of business segment | Segment			1
Number of shares awards deferred, unvested | shares			165,399		253,048
Deferred compensation arrangement with individual, shares vested | shares			105,577		17,927
Deferred Compensation Plans
Summary Of Significant Accounting Policies [Line Items]
Employer matching contributions, Vesting period			2 years
Vesting on Year One | Deferred Compensation Plans
Summary Of Significant Accounting Policies [Line Items]
Employer matching contributions, Vesting percentage			25%
Vesting on Year Two | Deferred Compensation Plans
Summary Of Significant Accounting Policies [Line Items]
Employer matching contributions, Vesting percentage			75%
Revenue Benchmark
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, customer	no	no	no	no
Minimum
Summary Of Significant Accounting Policies [Line Items]
Revenue, performance obligation, description of payment terms			30 days
Remaining lease terms	1 year		1 year
Maximum
Summary Of Significant Accounting Policies [Line Items]
Revenue, performance obligation, description of payment terms			90 days
Remaining lease terms	3 years		3 years
Commercial Customer | Revenue Benchmark | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10%	10%	10%	10%
Commercial Customer | Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, customer			no		one
Commercial Customer | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			10%		10%
BARDA
Summary Of Significant Accounting Policies [Line Items]
Number of performance obligations | PerformanceObligation			2
Total transaction price of contract			$ 9,200,000
RECELL system | BARDA
Summary Of Significant Accounting Policies [Line Items]
Product replacement obligation cost			$ 0
Number of units will be delivered			5,614
Transaction price allocated on a stand alone selling price basis			$ 7,600,000
Emergency Deployment | BARDA
Summary Of Significant Accounting Policies [Line Items]
Transaction price allocated on a stand alone selling price basis			$ 1,600,000
Emergency Deployment Service | Commercial Customer | Revenue Benchmark | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	1%	1%	1%	1%
Emergency Deployment Service | BARDA | Accounts Receivable Revenue | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage			4%		2%
General and Administrative Expense
Summary Of Significant Accounting Policies [Line Items]
Gain (loss) on foreign currency transactions	$ (6,000)	$ 7,000	$ (15,000)	$ (8,000)
General and Administrative Expense | Non-US
Summary Of Significant Accounting Policies [Line Items]
Gain (loss) on foreign currency transactions		$ 69,000	11,000	$ 47,000
Revenue | RECELL system | BARDA
Summary Of Significant Accounting Policies [Line Items]
Transaction price allocated on a stand alone selling price basis			$ 1,600,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Other Receivables (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Other Receivables Net Current [Abstract]
BARDA procurement and emergency preparedness services	$ 16	$ 16
BARDA expense reimbursements	426	882
Total	$ 442	$ 898

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Estimated Fair Values of Debt Securities Available for Sale (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	$ 28,641	$ 61,601
Gross Unrealized Holding Gains, Current marketable securities		1
Gross Unrealized Holding Losses, Current marketable securities	(79)	(424)
Carrying Value, Current marketable securities	28,562	61,178
Amortized Cost, Long-term marketable securities	2,759	6,933
Gross Unrealized Holding Gains, Long-term marketable securities	2	7
Gross Unrealized Holding Losses, Long-term marketable securities	(7)	(10)
Carrying Value, Long-term marketable securities	2,754	6,930
Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	31,668
Gross Unrealized Holding Gains	1
Carrying Value	31,669
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	1,422	3,865
Gross Unrealized Holding Losses, Current marketable securities	(5)	(23)
Carrying Value, Current marketable securities	1,417	3,842
U.S Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	23,227	43,092
Gross Unrealized Holding Gains, Current marketable securities		1
Gross Unrealized Holding Losses, Current marketable securities	(69)	(393)
Carrying Value, Current marketable securities	23,158	42,700
Amortized Cost, Long-term marketable securities		2,416
Gross Unrealized Holding Losses, Long-term marketable securities		(6)
Carrying Value, Long-term marketable securities		2,410
U.S Treasury Securities | Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	999
Gross Unrealized Holding Gains	1
Carrying Value	1,000
Money Market Funds | Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	30,669	14,089
Carrying Value	30,669	14,089
U.S Government Agency Obligations
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	1,681	1,901
Gross Unrealized Holding Losses, Current marketable securities	(5)	(8)
Carrying Value, Current marketable securities	1,676	1,893
Amortized Cost, Long-term marketable securities		949
Gross Unrealized Holding Losses, Long-term marketable securities		(1)
Carrying Value, Long-term marketable securities		948
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	2,311	12,743
Carrying Value, Current marketable securities	2,311	12,743
Asset-backed Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Long-term marketable securities	2,759	3,568
Gross Unrealized Holding Gains, Long-term marketable securities	2	7
Gross Unrealized Holding Losses, Long-term marketable securities	(7)	(3)
Carrying Value, Long-term marketable securities	$ 2,754	$ 3,572

Marketable Securities - Summa_2

Marketable Securities - Summary of Maturities of Debt Securities Available for Sale (Detail) - Contractual Maturities - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Available for sale securities, Due in one year or less, Amortized cost	$ 28,641	$ 61,601
Due after one year through three years	2,759	6,933
Available for sale securities, Due in one year or less, Carrying value	28,562	61,178
Due after one year through three years	$ 2,754	$ 6,930

Marketable Securities - Additio

Marketable Securities - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Unrealized gain on marketable securities	$ 3,000	$ 8,000
Unrealized loss on marketable securities	86,000	426,000
Net unrealized loss on marketable securities	83,000	434,000
Credit loss recognized	0	0
Prepaids and Other Current Assets
Schedule Of Available For Sale Securities [Line Items]
Accrued interest income	$ 168,000	$ 168,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	$ 28,562	$ 61,178
Total long-term marketable securities	2,754	6,930
Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	31,669
Total current marketable securities	28,562	61,178
Total long-term marketable securities	2,754	6,930
Total marketable securities and cash equivalents	62,985	82,197
Fair Value on Recurring Basis | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	30,669
Total marketable securities and cash equivalents	30,669	14,089
Fair Value on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	1,000
Total current marketable securities	28,562	61,178
Total long-term marketable securities	2,754	6,930
Total marketable securities and cash equivalents	32,316	68,108
Fair Value on Recurring Basis | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	30,669	14,089
Fair Value on Recurring Basis | Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	30,669	14,089
Fair Value on Recurring Basis | U.S Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	1,000
Total current marketable securities	23,158	42,700
Total long-term marketable securities		2,410
Fair Value on Recurring Basis | U.S Treasury Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	1,000
Total current marketable securities	23,158	42,700
Total long-term marketable securities		2,410
Fair Value on Recurring Basis | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	2,311	12,743
Fair Value on Recurring Basis | Commercial Paper | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	2,311	12,743
Fair Value on Recurring Basis | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	1,417	3,842
Fair Value on Recurring Basis | Corporate Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	1,417	3,842
Fair Value on Recurring Basis | U.S Government Agency Obligations
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	1,676	1,893
Total long-term marketable securities		948
Fair Value on Recurring Basis | U.S Government Agency Obligations | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total current marketable securities	1,676	1,893
Total long-term marketable securities		948
Fair Value on Recurring Basis | Asset-backed Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total long-term marketable securities	2,754	3,572
Fair Value on Recurring Basis | Asset-backed Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total long-term marketable securities	$ 2,754	$ 3,572

Revenues - Additional Informati

Revenues - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) PerformanceObligation	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract description			For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations: (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services.
Capitalized fulfilment costs	$ 126,000		$ 126,000		$ 252,000
Performance obligation estimated revenue expected to be recognized	557,000		557,000		698,000
Contract with customer assets	0		0		0
Contract with customer liabilities	557,000		557,000		698,000
Contract with customers non current liability	374,000		374,000		698,000
Contract with customer liability revenue recognized		$ 0		$ 0
Contract cost amortization			170,000	169,000
Contract cost impairment loss	0	0	0	0
Cost of Sales
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract cost amortization	85,000	84,000	170,000	169,000
Prepaids and Other Current Assets
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Capitalized fulfilment costs	126,000		126,000		252,000
Other Current Liabilities
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract with customers current liability	183,000		183,000		0
Contract Liabilities
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract with customers non current liability	374,000		$ 374,000		698,000
BARDA
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract description			For the contract with BARDA, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services.
Number of performance obligations | PerformanceObligation			2
Contract with customer liability revenue recognized	67,000	93,000	$ 160,000	186,000
BARDA | RECELL system
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Number of units will be delivered			5,614
Product replacement obligation cost			$ 0
Deferred cost	130,000		130,000		194,000
Services recognized	67,000	$ 93,000	160,000	$ 186,000
Performance obligation estimated revenue expected to be recognized	149,000		149,000		274,000
Japanese Pharmaceuticals and Medical Device Act Approval | RECELL system
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation estimated revenue expected to be recognized	408,000		408,000		$ 424,000
COSMOTEC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract with customer liability revenue recognized	$ 8,000		$ 17,000

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Feb. 28, 2023
Leases [Abstract]
Increase in operating lease ROU assets and operating lease liabilities			$ 1,100,000
Lessee operating lease commencement term	2023-07
Lease term	5 years	5 years
Average monthly rent charge		$ 25,000

Leases - Summary Of Lease Cost

Leases - Summary Of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lease Cost [Abstract]
Operating lease cost	$ 197	$ 194	$ 395	$ 388
Variable lease cost	13	13	26	25
Total lease cost	$ 210	$ 207	$ 421	$ 413

Leases - Summary Of Supplementa

Leases - Summary Of Supplemental Cash Flow Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Abstract]
Operating cash outflows from operating leases	$ 205	$ 199	$ 410	$ 397

Leases - Summary Of Supplemen_2

Leases - Summary Of Supplemental Balance Sheet Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Disclosure Of Supplemental Balance Sheet Information Related To Operating Leases [Abstract]
Operating lease right-of-use assets	$ 1,651	$ 851
Total right-of-use assets	1,651	851
Operating lease liabilities, short-term	$ 656	$ 612
Operating Lease Liability Current Statement Of Financial Position Extensible List	Other current liabilities	Other current liabilities
Operating lease liabilities, long-term	$ 1,047	$ 306
Total operating lease liabilities	$ 1,703	$ 918
Operating lease weighted average remaining lease term (years)	2 years 8 months 23 days	1 year 5 months 8 days
Operating lease weighted average discount rate	7.93%	6.71%

Leases - Summary Of Maturities

Leases - Summary Of Maturities Of The Company's Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Operating Lease Liabilities Payments Due [Abstract]
Remainder of 2023	$ 345
2024	741
2025	441
2026	377
Total lease payments	1,904
Less imputed interest	(201)
Total operating lease liabilities	$ 1,703	$ 918

Inventory - Summary Of Composit

Inventory - Summary Of Composition Of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 1,882	$ 1,131
Work in process	491	384
Finished goods	685	610
Total inventory	$ 3,058	$ 2,125

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Inventory Disclosure [Abstract]
Excess and obsolete inventory related charges	$ 2,000	$ 61,000	$ 68,000	$ 158,000

Intangible Assets - Summary Of

Intangible Assets - Summary Of Composition Of Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 567	$ 558
Finite Lived Intangible Assets, Accumulated Amortization	(111)	(93)
Finite Lived Intangible Assets, Net Carrying Amount	402
Intangible Assets, Net (Excluding Goodwill)	456	465
Trademarks
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 54	54
Patent 1
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years
Finite Lived Intangible Assets, Gross Amount	$ 17	17
Finite Lived Intangible Assets, Accumulated Amortization	(16)	(16)
Finite Lived Intangible Assets, Net Carrying Amount	$ 1	1
Patent 2
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	13 years
Finite Lived Intangible Assets, Gross Amount	$ 138	137
Finite Lived Intangible Assets, Accumulated Amortization	(33)	(28)
Finite Lived Intangible Assets, Net Carrying Amount	$ 105	109
Patent 3
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite Lived Intangible Assets, Gross Amount	$ 195	194
Finite Lived Intangible Assets, Accumulated Amortization	(46)	(39)
Finite Lived Intangible Assets, Net Carrying Amount	$ 149	155
Patent 5
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Finite Lived Intangible Assets, Gross Amount	$ 98	89
Finite Lived Intangible Assets, Accumulated Amortization	(9)	(6)
Finite Lived Intangible Assets, Net Carrying Amount	$ 89	83
Patent 6
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Finite Lived Intangible Assets, Gross Amount	$ 44	43
Finite Lived Intangible Assets, Accumulated Amortization	(5)	(4)
Finite Lived Intangible Assets, Net Carrying Amount	$ 39	39
Patent 7
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	13 years
Finite Lived Intangible Assets, Gross Amount	$ 2	2
Finite Lived Intangible Assets, Net Carrying Amount	$ 2	2
Patent 8
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Finite Lived Intangible Assets, Gross Amount	$ 10	13
Finite Lived Intangible Assets, Accumulated Amortization	(1)
Finite Lived Intangible Assets, Net Carrying Amount	$ 9	13
Patent 10
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Finite Lived Intangible Assets, Gross Amount	$ 3	3
Finite Lived Intangible Assets, Net Carrying Amount	$ 3	3
Patent 11
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Finite Lived Intangible Assets, Gross Amount	$ 6	6
Finite Lived Intangible Assets, Accumulated Amortization	(1)
Finite Lived Intangible Assets, Net Carrying Amount	$ 5	$ 6

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Impairment of intangible assets	$ 4,000	$ 0	$ 4,000	$ 0
Amortization of intangible assets	$ 8,000	$ 8,000	17,000	$ 42,000
Impairment charge			$ 4,000

Intangible Assets - Summary o_2

Intangible Assets - Summary of Future Amortization of Amortizable Intangible assets held (Detail) $ in Thousands	Jun. 30, 2023 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2023	$ 17
2024	34
2025	34
2026	34
2027	33
2028	33
Thereafter	217
Finite Lived Intangible Assets, Net Carrying Amount	$ 402

Plant and Equipment - Summary O

Plant and Equipment - Summary Of Composition Of Property, Plant And Equipment (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Less: accumulated amortization and depreciation	$ (2,391)	$ (2,152)
Total plant and equipment, net	$ 1,598	1,200
Computer Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 889	755
Computer Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 980	871
Construction In Progress
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 423	258
Furniture And Fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Property, Plant and Equipment, Gross	$ 616	439
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 696	643
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Useful Lives	Lesser of life or lease term
Property, Plant and Equipment, Gross	$ 257	257
RECELL Moulds
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 128	$ 129

Plant and Equipment - Additiona

Plant and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property Plant And Equipment [Abstract]
Depreciation	$ 137,000	$ 129,000	$ 264,000	$ 258,000
Impairment charge	$ 3,000		$ 3,000
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]	General And Administrative Expense		General And Administrative Expense

Other Current and Long-Term A_3

Other Current and Long-Term Assets and Liabilities - Summary of Prepaids and Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 1,375	$ 921
Lease deposits		110
Accrued investment income	168	168
BARDA contract costs	126	252
Other receivables	525	127
Total prepaids and other current assets	$ 2,194	$ 1,578

Other Current and Long-Term A_4

Other Current and Long-Term Assets and Liabilities - Summary of Other Long Term Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Other Assets Noncurrent Disclosure [Abstract]
Long-term lease deposits	$ 189	$ 25
Long-term prepaids	96	97
Total other long-term assets	$ 285	$ 122

Other Current and Long-Term A_5

Other Current and Long-Term Assets and Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Other Liabilities Current [Abstract]
Operating lease liability	$ 656	$ 612
BARDA deferred costs	130	194
BARDA deferred revenue	183
Other current liabilities	232	184
Total other current liabilities	$ 1,201	$ 990

Reporting Segment and Geograp_3

Reporting Segment and Geographic Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 Segment
Segment Reporting [Abstract]
Number of reporting segment	1

Reporting Segment and Geograp_4

Reporting Segment and Geographic Information - Schedule Of Revenue and Cost Of Sales By Region and Customer Type (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue:
Revenues	$ 11,753	$ 8,335	$ 22,303	$ 15,874
Cost of sales
Cost of sales	2,204	1,386	3,871	3,164
BARDA deferred costs			(64)	(64)
Commercial Sales
Revenue:
Revenues	11,686	8,242	22,143	15,688
Cost of sales
Cost of sales	2,108	1,302	3,724	3,007
Services For Emergency Preparedness
Revenue:
Revenues	67	93	160	186
Product Cost
Cost of sales
BARDA deferred costs	11		(23)	(12)
Emergency Preparedness Service Cost
Cost of sales
BARDA deferred costs	85	84	170	169
United States
Revenue:
Revenues	10,992	8,278	20,417	15,676
Japan
Revenue:
Revenues	708		1,729
Australia
Revenue:
Revenues	33	29	95	116
United Kingdom
Revenue:
Revenues	$ 20	$ 28	$ 62	$ 82

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Threatened Litigation
Litigation liability	$ 0	$ 0

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Common stock shares authorized	200,000,000	200,000,000
Common stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock par value	$ 0.0001	$ 0.0001
Common stock shares issued	25,447,615	25,208,436
Common stock shares outstanding	25,447,615	25,208,436
Preferred stock shares outstanding	0	0
Shareholders Of Avita Medical | ADRS
Class Of Stock [Line Items]
Reverse stock split ratio, description	One share of common stock on Nasdaq is equivalent to five CDIs on the ASX.

Stock-Based Payment Plans - Add

Stock-Based Payment Plans - Additional Information (Detail) - USD ($) $ in Thousands				1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 06, 2023	Dec. 12, 2022	Dec. 22, 2021	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Nov. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation					$ 1,100	$ 1,400	$ 3,800	$ 4,300
Income tax benefit (expense)					$ 0	$ 0	$ 0	$ 0
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested							92,650
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number				378,541	378,541		378,541		460,518
Number of shares registered under Employee Stock Purchase Plan				1,000,000
Maximum shares purchased under employee stock purchase plan during offering period				5,000
Employee stock purchase plan effective date				Jul. 01, 2023
Non Option Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested							15,750
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number				42,021	42,021		42,021		65,646
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage by which purchase price of shares lower fair market value of common stock				85%
Maximum percentage of payroll deductions allowed to purchase common stock				15%
2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement contractual term of awards							10 years
2020 Plan | Vesting Period One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period							3 years
2020 Plan | Vesting Period Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period							4 years
2020 Plan | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement number of shares authorised for issuance										1,750,000
Share based compensation by share based payment arrangement number of additional shares authorised							2,500,000
Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Reverse stock split							reverse stock split of 100:1
2021 Annual Meeting Awards | Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period			12 months
Aggregate number of options and RSU			68,600
Tenure awards to Board of Director			41,400
Tenure option awards to Board of Director			15,300
Tenure awards granted to Board of Director			6,900
Tenure option awards granted to Board of Director			2,550
2021 Annual Meeting Awards | Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage			33.33%
Tenure awards to Board of Director			27,200
Tenure option awards to Board of Director			9,850
Tenure awards granted to Board of Director			13,600
Tenure option awards granted to Board of Director			4,925
2021 Annual Meeting Awards | Restricted Stock Units (RSUs) | Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director			26,100
Tenure RSU awards granted to Board of Director			4,350
2021 Annual Meeting Awards | Restricted Stock Units (RSUs) | Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director			17,350
Tenure RSU awards granted to Board of Director			8,675
2022 Annual Meeting Awards | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage		25%
Aggregate number of options and RSU		226,296
2022 Annual Meeting Awards | Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period		12 months
Aggregate number of options and RSU		71,936
Tenure option awards to Board of Director		21,580
2022 Annual Meeting Awards | Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure option awards to Board of Director		5,359
Tenure awards granted to Board of Director		17,984
2022 Annual Meeting Awards | Restricted Stock Units (RSUs) | Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director		50,356
2022 Annual Meeting Awards | Restricted Stock Units (RSUs) | Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director		12,589
2023 Annual Meeting Awards | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage	33.30%
Aggregate number of options and RSU	100,000
2023 Annual Meeting Awards | Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period	12 months
Aggregate number of options and RSU	82,566
Tenure awards to Board of Director	52,926
Tenure option awards to Board of Director	15,876
Tenure awards granted to Board of Director	8,821
Tenure RSU awards granted to Board of Director							2,646
2023 Annual Meeting Awards | Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage	33.33%
Tenure awards to Board of Director	29,640
Tenure option awards to Board of Director	8,892
Tenure awards granted to Board of Director	14,820
Tenure option awards granted to Board of Director	4,446
2023 Annual Meeting Awards | Restricted Stock Units (RSUs) | Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director	37,050
Tenure RSU awards granted to Board of Director	6,175
2023 Annual Meeting Awards | Restricted Stock Units (RSUs) | Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director	20,748
Tenure RSU awards granted to Board of Director	10,374

Stock-Based Payment Plans - Sum

Stock-Based Payment Plans - Summary Of Stock-based Compensation Is Reflected In The Statements Of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	$ 1,143	$ 1,414	$ 3,783	$ 4,346
Selling and Marketing Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	76	285	401	614
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	818	983	2,908	3,310
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	$ 249	$ 146	$ 474	$ 422

Stock-Based Payment Plans - S_2

Stock-Based Payment Plans - Summary Of Share Option Activity (Detail) - shares	6 Months Ended
	Jun. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	2,235,446
Granted	889,193
Exercised	(146,529)
Expired	(237,281)
Forfeited	(65,371)
Ending balance	2,675,458
Exercisable	956,199
Service Only Share Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	1,724,252
Granted	889,193
Exercised	(116,529)
Expired	(59,125)
Forfeited	(58,413)
Ending balance	2,379,378
Exercisable	720,303
Performance Based Share Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	511,194
Exercised	(30,000)
Expired	(178,156)
Forfeited	(6,958)
Ending balance	296,080
Exercisable	235,896

Stock-Based Payment Plans - S_3

Stock-Based Payment Plans - Summary Of Company Unvested RSUs (Detail)	6 Months Ended
	Jun. 30, 2023 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs beginning balance	460,518
Unvested RSUs granted	57,798
Unvested RSUs vested	(92,650)
Unvested RSUs forfeited	(47,125)
Unvested RSUs ending balance	378,541
Non Options Tenure Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs beginning balance	394,872
Unvested RSUs granted	57,798
Unvested RSUs vested	(76,900)
Unvested RSUs forfeited	(39,250)
Unvested RSUs ending balance	336,520
Non Option Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs beginning balance	65,646
Unvested RSUs vested	(15,750)
Unvested RSUs forfeited	(7,875)
Unvested RSUs ending balance	42,021

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Line Items]
Provision for income tax	$ 13,000	$ 4,000	$ 43,000	$ 8,000

Net Loss per Share - Summary of

Net Loss per Share - Summary of Reconciliation of The Basic And Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement [Table]
Net Loss	$ 10,384	$ 6,261	$ 19,604	$ 15,724
Weighted-average common shares – outstanding, basic	25,239,723	24,971,243	25,221,009	24,954,712
Weighted-average common shares – outstanding, diluted	25,239,723	24,971,243	25,221,009	24,954,712
Net loss per common share, basic	$ (0.41)	$ (0.25)	$ (0.78)	$ (0.63)
Net loss per common share, diluted	$ (0.41)	$ (0.25)	$ (0.78)	$ (0.63)

Net Loss per Share - Summary _2

Net Loss per Share - Summary of Anti-dilutive shares Excluded From Diluted Net Loss Per Common share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock options
Statement [Table]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)	2,675,458	1,774,070	2,675,458	1,774,070
Restricted Stock Units (RSUs)
Statement [Table]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)	378,541	220,920	378,541	220,920

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2023 shares
Earnings Per Share [Abstract]
Aggregate number of common equivalent shares excluded from computations of diluted net loss per common share (in shares)	105,577

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan employers matching contribution percentage of employees pay			6%
Employers contribution to retirement plan	$ 249,000	$ 239,000	$ 671,000	$ 471,000
Deferred compensation plan liability	3,800,000		$ 3,800,000		$ 1,300,000
Number of shares awards deferred, unvested			165,399		253,048
Deferred compensation arrangement with individual, shares vested			105,577		17,927
Payout of deferred compensation liability for a terminated employee	82,000
Deferred compensation arrangement with individual, vested redemption value			$ 892,000		$ 127,000
Other Current Liabilities
Defined Benefit Plan Disclosure [Line Items]
Deferred compensation plan liability	2,600,000		$ 2,600,000		78,000
Non-Qualified Deferred Compensation Plans
Defined Benefit Plan Disclosure [Line Items]
Employer matching contributions, Vesting period			2 years
Employer contributions to deferred compensation plan	39,000	$ 38,000	$ 80,000	$ 122,000
Deferred compensation plan liability	$ 1,200,000		$ 1,200,000		$ 1,300,000
Non-Qualified Deferred Compensation Plans | Vesting on Year One
Defined Benefit Plan Disclosure [Line Items]
Employer matching contributions, Vesting percentage			25%
Non-Qualified Deferred Compensation Plans | Vesting on Year Two
Defined Benefit Plan Disclosure [Line Items]
Employer matching contributions, Vesting percentage			75%
Non-Qualified Deferred Compensation Plans | Minimum
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan employers matching contribution percentage of employees pay			4%
Non-Qualified Deferred Compensation Plans | Maximum
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan employers matching contribution percentage of employees pay			6%

Retirement Plans - Summary of F

Retirement Plans - Summary of Fair Values of Company's Deferred Compensation Plan Assets and Liability (Detail) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Non-qualified deferred compensation liability		$ 1,224	$ 1,270
Non-Qualified Deferred Compensation Plans
Defined Benefit Plan Disclosure [Line Items]
Corporate-owned life insurance policies	[1]	2,091	1,238
Non-qualified deferred compensation liability	[2]	3,796	1,348
Non-Qualified Deferred Compensation Plans | Level 2
Defined Benefit Plan Disclosure [Line Items]
Corporate-owned life insurance policies	[1]	2,091	1,238
Non-qualified deferred compensation liability	[2]	$ 3,796	$ 1,348
[1] The corporate-owned life insurance contracts are recorded at cash surrender value, which is provided by a third party and reflects the net asset value of the underlying publicly traded mutual funds and are categorized as Level 2. Non-qualified deferred compensation plan liability is measured at fair value based on quoted prices of identical instruments to the investment vehicles selected by the participants.

Retirement Plans - Summary of E

Retirement Plans - Summary of Eligible Share Award Activity (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Change in classification of deferred compensation share awards	$ (192)		$ (192)
Stock-based compensation expense		$ 3,783	$ 4,346
Non-qualified | Deferred Compensation Plans
Defined Benefit Plan Disclosure [Line Items]
Balance at inception/beginning of period		557
Change in classification of deferred compensation share awards				$ 192
Stock-based compensation expense		411		471
Change in redemption value		1,025		21
Vesting of share awards held by NDQC		(765)		(127)
Ending Balance		$ 1,228		$ 557